

CURRICULUM VITAE

LARA A. RAY, PhD
University of California, Los Angeles
3214 Franz Hall
Los Angeles, CA 90095
Phone: 310-794-5383
Email: lararay@psych.ucla.edu

ACADEMIC APPOINTMENTS

Jan 2019-2022 **Shirley M. Hatos Term Chair in Clinical Neuropharmacology**
Department of Psychiatry and Biobehavioral Sciences
School of Medicine
University of California, Los Angeles

Jul 2016 - **Full Professor** (with tenure)
Department of Psychology (Clinical Area)
University of California, Los Angeles

Jul 2013-Jun 2016 **Associate Professor** (with tenure)
Department of Psychology (Clinical Area)
University of California, Los Angeles

Jul 2008-Jun 2013 **Assistant Professor**
Department of Psychology (Clinical Area)
University of California, Los Angeles

Jul 2010 - **Faculty Member**
Department of Psychiatry and Biobehavioral Sciences
School of Medicine
University of California, Los Angeles

Mar 2009 - **Faculty Member**
Brain Research Institute
University of California, Los Angeles

Jul 2009 – Jun 2015 **Co-Director**
Addiction and Behavioral Medicine Clinic
UCLA Family Health Center
University of California, Los Angeles

EDUCATION

Jul 2007-Jun 2008 **Postdoctoral Fellow**
Center for Alcohol and Addiction Studies
Brown University Medical School, Providence, Rhode Island
Specialty: Substance use disorders

Jul 2006-Jun 2007 **Clinical Psychology Intern, Adult Track**
Brown University Medical School, Department of Psychiatry and Human Behavior,
Providence, Rhode Island

Aug 2002-May 2007 **Doctor of Philosophy, Clinical Psychology**
University of Colorado at Boulder, Boulder, CO

Aug 2002-Oct 2006 **Interdisciplinary Graduate Certificate, Behavioral Genetics**
Institute for Behavioral Genetics, University of Colorado at Boulder, Boulder, CO

- May 2004** **Master of Arts, Clinical Psychology**
University of Colorado at Boulder, Boulder, CO
- Aug 2001** **Bachelor of Arts, Psychology, with honors**
San Diego State University, San Diego, CA

HONORS AND AWARDS

- 2022-2023** **President (elected),** Research Society on Alcoholism
- 2021** **Seixas Award for Service,** Research Society on Alcoholism
- 2019-2023** **Shirley M. Hatos Term Chair in Clinical Neuropharmacology,** UCLA Department of Psychiatry and Biobehavioral Sciences
- 2019** **J. Arthur Woodward Graduate Mentor Award,** UCLA Psychology Graduate Student Association
- 2018** **Distinguished Teaching Award,** UCLA Department of Psychology
- 2017** **Eva King Killam Award for Translational Research,** American College on Neuropsychopharmacology
- 2017** **Distinguished Scientific Award for Early Career Contribution to Psychology,** American Psychological Association
- 2015** **Fellow,** American Psychological Association Division 50, Society of Addiction Psychology
- 2014** **Young Investigator Award,** Research Society on Alcoholism
- 2013** **Early Career Award for Distinguished Scientific Contributions,** APA Division 50, Society of Addiction Psychology
- 2013** **David Shakow Early Career Award for Distinguished Scientific Contributions to Clinical Psychology,** APA Division 12, Society of Clinical Psychology
- 2012** **Presentation Award,** NIDA-NIAAA Early Career Session, American Psychological Association, Division 50 (Addictions)
- 2011** **Travel Award,** International Behavioral and Neural Genetics Society (IBANGS)
- 2010** **Travel Award,** American College of Neuropsychopharmacology (ACNP)
- 2010** **NIAAA Travel Award,** International Society for Biomedical Research on Alcoholism
- 2009** **NIH Loan Repayment Program Award,** Competitive Renewal
- 2009** **Travel Fellowship,** Winter Conference on Brain Research
- 2008** **Early Career Presentation Award,** American Psychological Association, Division 50
- 2008** **Young Investigator Award,** NIAAA-sponsored Conference on Alcoholism and Stress
- 2007** **Dozier Award** for Outstanding Graduate Student Research, Department of Psychology, University of Colorado at Boulder
- 2007** **NIH Loan Repayment Program Award**
- 2007** **Psychology Intern Research Poster Award,** Department of Psychiatry and Human Behavior, Brown Medical School, 11th Annual Research Symposium
- 2007** **Enoch Gordis Research Award,** Research Society on Alcoholism
- 2005** Finalist for the **Enoch Gordis Research Award,** Research Society on Alcoholism
- 2002-2003** Fellowship from the **National Science Foundation (NSF)** and the **Alliance for Graduate Education and the Professoriate (AGEP),** University of Colorado at Boulder
- 2001** **Graduation with Distinction in Psychology,** San Diego State University
- 2000-2001** **Dean's Academic Honor List,** San Diego State University

PROFESSIONAL LICENSES

- Oct 2008** **Licensed Clinical Psychologist,** California Board of Psychology,
License # 22240
- Sep 2013** **Board Certification in Clinical Psychology,** American Board of Professional Psychology,
Diploma #7405

GRANT FUNDING

(*Note: TDC = Total Direct Costs)

Active Research Support

NIAAA R01AA029701 Ray (PI)
 Translational underpinnings of motivation for alcohol in humans
 This proposal seeks to translate a progressive ratio alcohol administration task to elucidate the Addiction Neuroclinical Assessment (ANA) and its role in motivation for alcohol in humans.
Role: PI TDC \$1,677,348 Project Period: 08/17/2023-07/31/2027

Department of Defense AS210006-A2 Ray (PI)
 Pharmacotherapies for Alcohol and Substance Use Disorders Alliance (PASA) Program
 Development of suvorexant for the treatment of alcohol use disorder and posttraumatic stress disorder.
 This planning grant and subsequent clinical trial tests the effects of suvorexant for the treatment of AUD and comorbid PTSD in veteran and non-veteran populations. Clinical trial award is pending the successful completion of the planning grant. Multi-site trial with Ray (PI-UCLA) and Lane (PI-UTHealth-Houston).
Role: PI TDC \$753,601 Project Period: 01/15/2023-01/15/2026

NIAAA R01AA026190 Ray (PI)
 A randomized controlled clinical trial of the neuroimmune modulator ibudilast for the treatment of AUD
 This proposal seeks to advance medication development for alcohol use disorder by conducting a 12-week, double-blind, placebo-controlled randomized trial of ibudilast
Role: PI TDC \$1,892,000 Project Period: 05/01/2018-04/30/2024 (NCE)

NIAAA R01AA029703 Magill (PI)
 Optimal endpoints in clinical trials of cognitive behavioral interventions for AOD: An aggregate and individual patient data meta-analysis.
 This study will conduct a comprehensive and state-of-the-art meta-analysis of Cognitive Behavioral Therapy efficacy, moderated efficacy, and mediating processes for the treatment of alcohol or other drug use disorders.
Role: Co-Investigator TDC \$1,594,952 Project Period: 09/01/2022-08/31/2026

NIAAA K24AA025704 Ray (PI)
 Clinical neuroscience of alcoholism: integrating neuroscience and clinical trials
 This midcareer investigator award in patient-oriented research seeks to support the PI in her efforts in mentoring and clinical research in the field of alcoholism
Role: PI TDC \$851,575 Project Period: 09/15/2018-08/31/2024 (NCE)

NIAAA R21AA030643 Ray (PI)
 The effects of stress on decision-making in alcohol use disorder: A translational approach.
 This study will test the effects of acute stress and its underlying neurocircuitry on decision making among individuals with alcohol use disorder and matched controls.
Role: PI TDC \$275,000 Project Period: 03/14/2023-02/28/2025

NIAAA R21AA029771 Ray (PI)
 Integrating findings across stages of medication development for AUD
 This study will employ novel meta-analytic methods to examine evidence of medication efficacy for AUD across preclinical, human laboratory, and clinical trials.
Role: PI TDC \$275,000 Project Period: 09/20/2021-08/31/2024 (NCE)

NIAAA 75N94021F00002 Ray/Shoptaw (MPI)
 Alcohol Cue Human Laboratory Study Testing ASP-8062

The purpose of this contract is to advance medication development for alcohol use disorder by participating as a clinical site in a human laboratory trial to test a new compound, ASP-8062.

Role: Co-PI TDC \$400,079 Project Period: 09/17/2021-12/16/2023

NIDA T32DA024635

Wassum/Ray (MPI)

UCLA Training Program in the Translational Neuroscience of Drug Abuse (TNDA)

This is a training grant in addiction science supports 4 predoctoral and 3 postdoctoral trainees. Drs. Wassum and Ray assumed leadership of the program in 2022 and submitted a competitive renewal.

Role: Co-PI TDC \$316,372 Project Period: 07/01/2022-06/30/2024 (NCE)

NIAAA 75N94021D00008

Ray/Shoptaw (MPI)

NIAAA Medications Development Clinical Investigations Network for the Treatment of Alcohol Use Disorder – Clinical Sites

The purpose of this contract is to advance medication development for alcohol use disorder by participating as a clinical site in multiple NIAAA Clinical Investigations Network trials.

Role: Co-PI TDC \$322,211 Project Period: 03/15/2021-03/14/2028

Completed Research Support

NIAAA

R21AA027180

Ray (PI)

A novel human laboratory model for screening medications for alcohol use disorder

This study will validate a novel clinical paradigm for testing the initial efficacy of pharmacotherapies for alcohol use disorder.

Role: PI TDC \$262,500 Project Period: 09/20/2019-08/31/2022

NIAAA

R03AA029244

Ray (PI)

Identifying treatment responders in medication trials for AUD using machine learning approaches

This proposal uses a machine learning approach to identify treatment responders by analyzing data across four multi-site clinical trials for AUD conducted by the NIAAA Clinical Investigations Group (NCIG).

Role: PI TDC \$100,000 Project Period: 07/01/2021-06/30/2023

NIAAA

R21 AA026006

Magill (PI)

A Meta-Analysis of CBT/RP Efficacy, Moderated Efficacy, and Mediation

The purpose of this study is to conduct a state-of-the-art meta-analysis of CBT/RP efficacy, moderated efficacy, and mediating processes.

Role: Co-I TDC \$313,147 Project Period: 10/01/2017-08/30/2020 (NCE)

NIAAA

R01AA026190S1 (Diversity Supplement)

Ray (PI)

A randomized controlled clinical trial of the neuroimmune modulator ibudilast for the treatment of AUD

The purpose of this diversity supplement is to support the research training of a PhD student from an underrepresented background and to test the effects of ibudilast on executive function.

Role: PI/Mentor TDC \$141,661 Project Period: 05/01/2019-02/28/2022

NIAAA

R21AA027180S1 (Diversity Supplement)

Ray (PI)

A novel human laboratory model for screening medications for alcohol use disorder

The purpose of this diversity supplement is to support the research training of a post-baccalaureate trainee from an underrepresented background and to test the effects of sleep on alcohol abstinence.

Role: PI/Mentor TDC \$83,641 Project Period: 09/01/2020-08/31/2022

NIDA

R01DA041226

Ray (PI)

Combining varenicline and naltrexone for smoking cessation and drinking reduction

This proposal is to conduct a randomized clinical trial comparing varenicline alone to varenicline plus naltrexone for smoking cessation in heavy drinking smokers.

Role: PI TDC \$1,500,000 Project Period: 09/01/2015-05/31/2019 (NCE)

NIH-NIDA R01DA041226-02S1 (Supplement) Ray (PI)

Combining varenicline and naltrexone for smoking cessation and drinking reduction: Sex differences

The purpose of this supplement is to examine the effect of sex as a marker of medication response.

Role: PI TDC: \$99,766 Project Period:09/01/2015-05/31/2019 (NCE)

NIAAA R01AA021744 Ray (PI)

Optimizing naltrexone for individuals of Asian descent

The purpose of this study is to optimize the use of naltrexone for alcoholism on the basis of pharmacogenetics.

Role: PI TDC \$750,000 Project Period: 07/01/2013-06/30/2017

TRDRP26IR-0021 Galvan (PI)

Longitudinal effects of nicotine on the developing adolescent brain

The goal of this grant is to identify the longitudinal effects of cigarette smoking on the developing adolescent brain in youth from diverse socioeconomic backgrounds.

Role: Co-I TDC \$366,467 Project Period: 07/01/2017-06/30/2019

HHSN27500008-1078-NCIG7-UCLA Ray (PI)

Randomized, Double Blind, Placebo-Controlled Trial of the Efficacy of Oxytocin for the Treatment of Alcohol Use Disorder

This project is a randomized, multisite clinical trial comparing oxytocin to placebo for the treatment of alcohol use disorders.

Role: PI TDC \$138,609 Project Period: 01/01/2018-06/30/2019

NIAAA R21AA022752 Ray (PI)

Modeling alcohol reward and reinforcement in the human laboratory

This study will test the association between subjective measures of alcohol reward and self-administration using state-of-the-art human laboratory paradigms.

Role: PI TDC \$275,000 Project Period: 09/10/2014-08/31/2017 (NCE)

HHSN27500003-1061-NCIG6-UCLA Ray/Shoptaw (Co-PIs)

Randomized, Double Blind, Placebo-Controlled Trial of the Safety and Efficacy of Gabapentin Enacarbil (Horizant®) Extended-Release Tablets for the Treatment of Alcohol Use Disorder

This project is a randomized, multisite clinical trial comparing Horizant to placebo for the treatment of alcohol use disorders.

Role: Co-PI TDC \$792,295 Project Period: 03/01/2015-01/30/2017

NIAAA R21AA023669 Ray/Karno (Co-PIs)

Perceived alcohol reward value and risk: Neural correlates and treatment effects

This study will examine the effects of a brief intervention for alcohol use disorder on neural markers of the incentive salience of alcohol.

Role: Co-PI TDC \$275,000 Project Period: 06/01/2015-05/31/2018 (NCE)

TRDRP 18KT-0020 Kirkpatrick (PI)

Therapeutic potential of oxytocin for nicotine addiction

This project investigates the dose-dependent acute effects of intranasal oxytocin on socioemotional emotional processing disruptions, craving, and smoking lapse during tobacco withdrawal.

Role: Co-I TDC \$240,000 Project Period: 07/01/2016 – 06/30/2018

NIAAA R01AA021744 (Diversity Supplement) Ray (PI)

Optimizing naltrexone for individuals of Asian descent

The purpose of this diversity supplement is to support the research training of a post-bac student from an underrepresented background and to help her achieve admission to a graduate program.

Role: PI/Mentor TDC \$70,588 Project Period: 09/01/2015-08/30/2016

NIAAA R34AA022055 Glassner-Edwards (PI)

Cell phone technology targeting ART and naltrexone adherence and alcohol use

This project uses mobile phone technology to deliver behavioral support for HIV-infected individuals with alcohol dependence treated with naltrexone.

Role: Co-I TDC \$450,000 Project Period: 07/01/2013-06/30/2016

NIAAA R21AA022214 Ray (PI)

Development of ibudilast as a novel treatment for alcohol dependence

This study consists of a series of human laboratory paradigms to test the initial efficacy of ibudilast, a glial cell modulator and phosphodiesterase inhibitor, for the treatment of alcoholism.

Role: PI TDC \$275,000 Project Period: 07/01/2013-06/30/2015

CTSI Seed Grant Ray (PI)

Repositioning ivermectin for the treatment of alcohol use disorders

This pilot study will examine safety and initial efficacy of ivermectin for the treatment of alcoholism.

Role: PI TDC \$157,199 Project Period: 09/01/2013-03/30/2015

NIDA R21 DA029831 Ray (PI)

Pharmacogenetics of naltrexone for methamphetamine use disorders

This study seeks to characterize the biobehavioral effects of naltrexone for methamphetamine use disorders and to extend its pharmacogenetics.

Role: PI TDC \$275,000 Project Period: 09/15/2011-08/31/2013

NIDA R21DA029831-01S1 Ray (PI)

Pharmacogenetics of naltrexone for methamphetamine use disorders (NIDA Summer Program Supplement)

The purpose of this supplement is to support three undergraduate students from underrepresented backgrounds to receive 10 weeks of research training in my research laboratory.

Role: PI/Mentor TDC \$30,000 Project Period: 06/25/2012-08/24/2012

NIDA R21DA029831-02S2 Ray (PI)

Pharmacogenetics of naltrexone for methamphetamine use disorders (NIDA Summer Program Supplement)

The purpose of this supplement is to support three undergraduate students from underrepresented backgrounds to receive 10 weeks of research training in my research laboratory.

Role: PI/Mentor TDC \$30,000 Project Period: 06/25/2013-08/24/2013

NIDA R03DA030898 Ray (PI)

Neuroimaging probes of medication response in smokers

The purpose of this project is to examine neural markers of response to a combined pharmacological treatment for heavy drinking smokers.

Role: PI TDC \$50,000 Project Period: 09/20/2010-08/31/2012

NIAAA R03AA19569 Ray (PI)

Integrating laboratory and neuroimaging phenotypes

The purpose of this project is to add a neuroimaging component to an ongoing laboratory study of subjective responses to alcohol and its underlying genetic determinants.

Role: PI TDC \$50,000 Project Period: 10/1/2009-09/30/2011

NIDA R03DA030898-01S1 Ray (PI)

Neuroimaging probes of medication response in smokers (NIDA Summer Program Supplement)

The purpose of this supplement is to support two undergraduate students from underrepresented backgrounds to receive 10 weeks of research training in my research laboratory.

Role: PI/Mentor TDC \$16,000 Project Period: 06/20/2011-08/26/2011

Hellman Fellowship UCLA Ray (PI)

The effects of naltrexone on the reinforcing properties of methamphetamine in the brain

This pilot study evaluated the effects of naltrexone on craving using an fMRI-based approach.

Role: PI TDC \$25,000 Project Period: 07/01/2011-06/30/2013

Faculty Research Grant UCLA Academic Senate Ray (PI)

The effects of alcohol on fear conditioning in humans

The purpose of this study is to test a human laboratory model of fear conditioning combined with an alcohol administration protocol which will provide the context for the conditioning paradigm.

Role: PI TDC \$5,000 Project Period: 07/01/2011-06/30/2013

NIAAA R21 AA020573 Moore (PI)

Reducing unhealthy alcohol use in older Hispanic day laborers

The purpose of this application is to develop and test a culturally-adapted intervention to reduce hazardous alcohol use in Hispanic day laborers.

Role: Co-I TDC \$275,000 Project Period: 04/01/2011-03/31/2013

NIAAA R03AA020186 Lee (PI)

Prospective predictors of alcohol expectancies in children with and without ADHD

This project will prospectively examine the development of alcohol expectancies and alcohol use in children.

Role: Co-I TDC \$50,000 Project Period: 06/20/2010-08/26/2012

TRDRP Shapiro (PI)

The effects of stereotype threat on smoking behavior

This project combines a stereotype threat manipulation with a human laboratory model of smoking and relapse. The goal is to examine the effects of stereotype threat on smoking behavior.

Role: Co-I TDC \$250,000 Project Period: 07/01/2011- 06/30/2013

Pfizer Global Award for Nicotine Dependence (GRAND) Ray (PI)

The effects of varenicline on stress-induced and cue-induced cigarette craving: a placebo-controlled laboratory study

This study will examine the effects of varenicline versus placebo on stress and cue-induced craving for cigarettes as they affect the relative reinforcing value of cigarettes.

Role: PI TDC \$160,000 Project Period: 11/01/2010-10/30/2012

TRDRP TRDRP 18KT-0020 Ray (PI)

Pharmacological interventions for heavy drinking smokers

The purpose of this project is to test the singular and combined effects of two medications (naltrexone and varenicline) for heavy drinking smokers in the laboratory.

Role: PI TDC \$285,000 Project Period: 07/01/2009-06/30/2012

ABMRF, the Foundation for Alcohol Research Ray (PI)
 Integrating human laboratory paradigms to refine alcoholism phenotypes
 The purpose of this study is to combine two human laboratory paradigms, intravenous alcohol administration and cue-exposure, to refine alcoholism phenotypes.

Role: PI TDC \$100,000 Project Period: 01/01/2009-06/30/2011

NIA P30AG021684
 Brief intervention for alcohol misuse among elderly Latino day laborers
 This pilot study will support initial survey and treatment development efforts designed to reduce risky alcohol use among Latino day laborers.

Role: Pilot project PI TDC \$20,000 Project Period: 09/20/2010-08/31/2011

NIH/UCLA Clinical Research Center M01-RR00865 Ray (PI)
 Support for three alcohol administration and pharmacotherapy studies to be conducted at the UCLA General Clinical Research Center (GCRC); Protocols #1593, 1605, and 1611. Financial support in addition to the access to the GCRC facilities, laboratory, and nursing staff

Role: PI TDC \$50,000 Project Period: 07/01/2009-06/30/2012

Faculty Research Grant UCLA Academic Senate Ray (PI)
 Pharmacogenetics of naltrexone in Asian Americans

The purpose of this study is to extend findings of naltrexone pharmacogenetics in Caucasian samples to individuals of Asian descent.

Role: PI TDC \$10,000 Project Period: 07/01/2009-06/30/2010

NIAAA R21 AA017273-01 Miranda (PI)

Mechanisms of naltrexone's action on drinking in adolescents

The purpose of this study is to improve our understanding of the efficacy and mechanisms of naltrexone for adolescents with alcohol dependence.

Role: Co-I TDC \$10,000 Project Period: 07/01/2008-06/30/2010

NIAAA T32 AA007459-20 Spirito (PI)

Research Training in Alcohol Treatment and Early Intervention Research

The purpose of this postdoctoral grant is to train PhD and MD postdoctoral fellows to carry out independent research in the field of alcohol research.

Role: Postdoctoral Research Fellow Project Period: 07/01/2007-06/30/2008

NIAAA F31 AA014847 Ray (PI)

Genetic Correlates of Alcohol Use Disorders

This NRSA provided training in state-of-the-art methods in genetic association studies and alcohol endophenotypes, including interdisciplinary training through the Institute for Behavioral Genetics at the University of Colorado at Boulder.

Role: PI Project Period: 04/30/2004-03/30/2007

Training grants to Dr. Ray's graduate students and post-doctoral fellows

NIAAA K01 AA029712 Grodin (PI)

Characterizing the microbiome-gut-brain axis in individuals with alcohol use disorder.

Role: Sponsor TDC: \$839,710 Project Period: 04/01/2022-03/31/2027

NIAAA F32AA029295 Meredith Broussard (PI)

Neuroimmune treatment for alcohol use disorder: Testing moderators of clinical response and mechanisms of action.

<u>Role:</u> Sponsor	TDC: \$127,044	Project Period: 06/01/2022-05/31/2025
NIAAA	F32AA029288	Nieto (PI)
Applying Behavioral Economics to Screen Medications for Alcohol Use Disorder		
This study will add a behavioral economics paradigm to an ongoing medication development and behavioral pharmacology project by the sponsor.		
<u>Role:</u> Sponsor	TDC: \$136,988	Project Period: 08/01/2020-07/31/2023
NIAAA	F31 AA028976	Burnette (PI)
Probing inflammation and reward sensitivity in alcohol use disorder		
This study will test the effect of an inflammatory challenge via endotoxin on reward sensitivity in AUD		
<u>Role:</u> Sponsor	TDC: \$ 112,011	Project Period: 09/01/2020-08/30/2023
NIAAA	F32 AA027699	Grodin (PI)
Elucidating the effects of neuroimmune modulation on neural substrates of alcohol cue and stress reactivity		
This study will investigate the effect of a novel pharmacotherapy on the neural response to alcohol cues and psychosocial stress in treatment-seeking individuals with alcohol use disorder.		
<u>Role:</u> Sponsor	TDC: \$ 117,692	Project Period: 07/01/2019-06/30/2021
Postdoctoral Fellowship Award T29DT0371		Lim (PI)
California Tobacco-Related Disease Research Program – Dynamic functional connectivity among heavy drinking smokers		
<u>Role:</u> Sponsor	TDC: \$45,058	Project Period: 04/01/2019-03/30/2020
Postdoctoral Fellowship Award T30DT0950		Green (PI)
California Tobacco-related Disease Research Program – Mediators and moderators of combined varenicline and naltrexone for smoking cessation		
<u>Role:</u> Sponsor	TDC: \$90,116	Project Period: 07/01/2019-06/30/2021
NIAAA	K01 AA026005	Roche (PI)
Development of minocycline as a neuroimmune therapy for alcohol use disorder		
<u>Role:</u> Sponsor	TDC: \$935,820	Project Period: 09/15/2017-08/31/2022
NIAAA	F32 AA023449	Yardley (PI)
Clinical assessment of ivermectin as a therapeutic agent to reduce alcohol intake		
<u>Role:</u> Sponsor	TDC: \$49,850	Project Period: 08/19/2014-08/18/2016
Postdoctoral Fellowship Award 309161		Roche (PI)
California Tobacco-related Disease Research Program - Effects of varenicline in heavy drinking smokers		
<u>Role:</u> Sponsor	TDC: \$145,000	Project Period: 08/01/2014-07/31/2017
NIDA	F31 DA035604	Courtney (PI)
The effects of naltrexone on neural responses to methamphetamine cues.		
<u>Role:</u> Sponsor	TDC \$47,000	Project Period: 10/01/2013-09/30/2015
NIAAA	F31 AA022569	Bujarski (PI)
The interplay between subjective response and self-administration of alcohol in the human laboratory.		
<u>Role:</u> Sponsor	TDC \$47,000	Project Period: 04/01/2014-03/30/2016

PUBLICATIONS

Citations: 12,090; H-index: 54 (Google Scholar, accessed September 2023)

Peer-Reviewed Publications

1. **Ray, L.A.**, & Hutchison, K. E. (2004). A polymorphism of the μ -opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcoholism Clinical and Experimental Research, *28*, 1789-1795.
2. Fromme, K., de Witt, H., Hutchison, K.E., **Ray, L.A.**, Corbin, W.R., Cook, T.A., & Wall, T.L. (2004). Biological and behavioral markers of alcohol sensitivity. Alcoholism Clinical and Experimental Research, *28*(2), 247-256.
3. Hines, L., **Ray, L.A.**, Hutchison, K.E., & Tabakoff, B. (2005). Alcoholism: The dissection for endophenotypes. Dialogues in Clinical Neuroscience, *7*(3), 153-163.
4. Hutchison, K.E., **Ray, L.A.**, Sandman, E., Rutter, M.C., Peters, A., & Swift, R. (2006). The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology, *31*, 1310-1317.
5. **Ray, L.A.**, McGeary, J., Marshall, E., & Hutchison, K.E. (2006). Risk factors for alcohol misuse: Examining heart rate response to alcohol, alcohol sensitivity, and personality constructs. Addictive Behaviors, *31*(11), 1959-1973.
6. **Ray, L.A.**, Hutchison, K.E., & Bryan, A. (2006). Psychosocial predictors of treatment outcome, dropout, and change processes in a pharmacological clinical trial for alcohol dependence. Addictive Disorders and Their Treatment, *5*(4), 179-190.
7. Bryan, A., **Ray, L.A.**, & Cooper, M.L. (2007). Alcohol use and protective sexual behaviors among high-risk adolescents: A prospective analysis. Journal of Studies on Alcohol and Drugs, *68*(3), 327-335.
8. **Ray, L.A.**, Meskew-Stacer, S., & Hutchison, K.E. (2007). The relationship between prospective self-rating of alcohol sensitivity and craving and experimental results from two alcohol challenge studies. Journal of Studies on Alcohol and Drugs, *68*(3), 379-384.
9. **Ray, L.A.**, Rhee, S.H., Stallings, M.S., Knopik, V., & Hutchison, K.E. (2007). Examining the heritability of a laboratory-based smoking endophenotype: Initial Results from an experimental twin study. Twin Research and Human Genetics, *10*(4), 546-553.
10. **Ray, L.A.**, Miranda, R. Jr., Kahler, C.M., Leventhal, A.M., Monti, P.M., Swift, R., & Hutchison, K.E. (2007). Pharmacological effects of naltrexone and intravenous alcohol on craving for cigarettes: A pilot study. Psychopharmacology, *193*(4), 449-456.
11. **Ray, L.A.**, & Hutchison, K.E. (2007). Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: A double-blind placebo-controlled study. Archives of General Psychiatry, *64*(9), 1069-1077.
12. **Ray, L.A.**, MacKillop, J., & Hutchison, K.E. (2007). Pharmacogenetics of the μ -opioid receptor and the treatment of addictions. Personalized Medicine, *4*(2), 217-220.
13. Miranda, R. Jr., Rohsenow, D.J., Monti, P.M., Tidey, J., & **Ray, L.A.** (2008). Effects of repeated days of smoking cue-exposure on urge to smoke and physiological reactivity. Addictive Behaviors, *33*(2), 347-353.
14. Miranda, R. Jr., MacKillop J., Monti, P.M., Rohsenow, D.J., Tidey, J., Gwaltney, C., Swift, R., **Ray, L.A.**, & McGeary, J.E. (2008). Effects of topiramate on urge to drink and the subjective effects of alcohol consumption. Alcoholism Clinical and Experimental Research, *32*(3), 489-497.
15. Leventhal, A.M., Kahler, C.W., **Ray, L.A.**, Stone, K., & Zimmerman, M. (2008). Anhedonia and amotivation in psychiatric outpatients with fully remitted stimulant use disorder. American Journal on Addictions, *17*(3), 218-223.
16. **Ray, L.A.**, Miranda Jr., R., Young, D., Chelminski, I., & Zimmerman, M. (2008). Diagnostic orphans for alcohol use disorders in a treatment-seeking psychiatric sample. Drug and Alcohol Dependence, *96*(1-2), 187-191.
17. MacKillop, J., Murphy, J.G., **Ray, L.A.**, Eisenberg, D.T.A., Lisman, S.A., Lum, J.K., & Wilson, D.S. (2008). Further validation of the cigarette purchase task for assessing the relative reinforcing efficacy of nicotine in college smokers. Experimental and Clinical Psychopharmacology, *16*(1), 57-65.

18. **Ray, L.A.**, Kahler, C., Young, D., Chelminski, I., & Zimmerman, M. (2008). The factor structure and severity of DSM-IV alcohol abuse and dependence symptoms in psychiatric outpatients. Journal of Studies on Alcohol and Drugs, *69*(4), 496-499.
19. **Ray, L.A.**, Hutchison, K.E., MacKillop, J., Miranda, R. Jr., Audette, A., Swift, R., & Monti, P.M. (2008). Effects of naltrexone during the descending limb of the blood alcohol curve. American Journal on Addictions, *17*(4), 257-264.
20. Haughey, H.M., **Ray, L.A.**, Finan, P., Villanueva, R., Nicolescu, M., & Hutchison, K.E. (2008). The Human GABA_A Receptor alpha 2 Gene Moderates the Acute Effects of Alcohol and Brain mRNA Expression. Genes, Brain, and Behavior, *7*(4), 447-454.
21. Filbey, F., **Ray, L.A.**, Smolen, A., Claus, E., Audette, A., & Hutchison, K.E. (2009). Differential neural response to alcohol priming and alcohol taste cues is associated with DRD4 VNTR and OPRM1 genotype. Alcoholism Clinical and Experimental Research, *32*(7), 1113-1123.
22. **Ray, L.A.**, Bryan, A., MacKillop, J., McGeary, J., Hesterberg, K. & Hutchison, K.E. (2009). The Dopamine D4 receptor (DRD4) gene exon III polymorphism, problematic alcohol use, and novelty seeking: direct and mediated genetic effects. Addiction Biology, *14*(2), 238-244.
23. MacKillop, J., Murphy, J.G., Tidey, J., Kahler, C., **Ray, L.A.**, & Bickel, W. (2009). Latent structure of the facets of alcohol reinforcement from a behavioral economic demand curve. Psychopharmacology, *203*(1), 33-40.
24. **Ray, L.A.**, MacKillop, J., Leggio, L., Morgan, M., & Hutchison, K.E. (2009). Effects of naltrexone on cortisol levels in heavy drinkers. Pharmacology, Biochemistry, and Behavior, *91*, 489-494.
25. Leventhal, A.M., Kahler, C.W., **Ray, L.A.**, & Zimmerman, M. (2009). Refining the depression-nicotine dependence link: patterns of depressive symptoms in psychiatric outpatients with current, past, and no history of nicotine dependence. Addictive Behaviors, *34*(3), 297-303.
26. **Ray, L.A.**, Miranda, R., Jr., MacKillop, J., McGeary, J. E., Tidey, J. W., Rohsenow, D. J., Gwaltney, C. J., Swift, R. M., & Monti, P. M. (2009). A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Experimental and Clinical Psychopharmacology, *17*, 122-9.
27. **Ray, L.A.**, Hutchison, K.E., Leventhal, A., Miranda, R. Jr., Francione, C., Young, D., Chelminski, I., & Zimmerman, M. (2009). Diagnosing alcohol abuse in alcohol dependent individuals: diagnostic and clinical implications. Addictive Behaviors, *34*, 587-92.
28. Magill, M., & **Ray, L.A.** (2009). Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis. Journal of Studies on Alcohol and Drugs, *70*, 516-27.
29. **Ray, L.A.**, & Hutchison, K.E. (2009). Associations among GABRG1, level of response to alcohol, and drinking behaviors. Alcoholism Clinical and Experimental Research, *33*(8), 1382-90.
30. Leggio, L., **Ray, L.A.**, Kenna, G., and Swift, R.M. (2009). Blood glucose level, alcohol heavy drinking, and alcohol craving during treatment for alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study. Alcoholism Clinical and Experimental Research, *33*(9), 1539-44
31. Leventhal, A.M., Waters, A.J., Kahler, C.W., **Ray, L.A.**, & Sussman, S. (2009). Relations between anhedonia and smoking motivation. Nicotine & Tobacco Research, *11*(9), 1047-54.
32. Witkiewitz, K., Holmes, A., **Ray, L.A.**, Murphy, J.G., Richardson, H.N., Chen, Y.-C., McDevitt-Murphy, M.E., Cruz, M.T., & Roberto, M. (2009). Young investigator award symposium. Alcohol, *43*, 499-508.
33. Miranda, R., **Ray, L.A.**, Justus, A., Meyerson, L.A., Knopik, V.S., McGeary, J., & Monti, P.M. (2010). Influence of the OPRM1 gene on adolescent alcohol misuse: mechanisms and moderators. Alcoholism Clinical and Experimental Research, *34*(1), 1-11.
34. **Ray, L.A.**, MacKillop, J., Leventhal, A., & Hutchison, K.E. (2009) Catching the alcohol buzz: an examination of the latent factor structure of subjective intoxication. Alcoholism Clinical and Experimental Research, *33*(12), 2154-2161.
35. **Ray, L.A.**, & Oslin, D.W. (2009). Naltrexone for the treatment of alcohol dependence among African Americans: Results from the COMBINE Study. Drug and Alcohol Dependence, *105*(3), 256-258.

36. **Ray, L.A.**, Capone, C., Sheets, E., Young, D., Chelminski, I., & Zimmerman, M. (2009). Posttraumatic stress disorder with and without alcohol use disorders: diagnostic and clinical correlates in a psychiatric sample. Psychiatry Research, *170* (2-3), 278-281.
37. MacKillop, J., Miranda, R., Jr., Monti, P. M., **Ray, L. A.**, Murphy, J.G., Rohsenow, D. J., McGeary, J. E., Swift, R. M., Tidey, J. W., & Gwaltney, C. J. (2010) Alcohol demand, delayed reward discounting, and craving in relation to drinking and alcohol use disorders. Journal of Abnormal Psychology, *119* (1), 106-114.
38. **Ray, L.A.**, Miranda Jr., R., Tidey, J.W., McGeary, J.E., MacKillop, J., Gwaltney, C.J., Rohsenow, D.J., Swift, R.M., & Monti, P.M. (2010). Polymorphisms of the μ -opioid receptor and dopamine D₄ receptor genes and subjective responses to alcohol in the natural environment. Journal of Abnormal Psychology, *119*(1), 115-125.
39. **Ray, L.A.**, Chin, P.F., & Miotto, K. (2010). Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics. CNS & Neurological Disorders – Drug Targets, *9*(1), 13-22.
40. **Ray, L.A.**, MacKillop, J., & Monti, P. (2010). Subjective responses to alcohol consumption as endophenotypes: advancing genetics into etiological and treatment models of alcoholism. Subst Use Misuse, *45*(11), 1742-1765.
41. **Ray, L.A.**, Hutchison, K.E., & Tartter, M. (2010). Application of human laboratory models to pharmacotherapy development for alcohol dependence. Curr Pharm Des, *16*(19), 2149-2158.
42. **Ray, L.A.**, Heydari, A., & Zorick, T. (2010). Quetiapine for the treatment of alcoholism: scientific rationale and review of the literature. Drug and Alcohol Review, *29*(5), 568-575.
43. MacKillop, J., O'Hagen, S., Lisman, S.A., Murphy, J.G., **Ray, L.A.**, McGeary, J.E., Tidey, J.W., & Monti, P.E. (2010). Behavioral economic analysis of cue-elicited craving for alcohol. Addiction, *105*(9), 1599-607.
44. **Ray, L.A.**, Hutchison, K.E., Ashenhurst, J., & Morrow, A.L. (2010). Naltrexone selectively elevates GABAergic neurosteroid levels in heavy drinkers with the Asp40 allele of the OPRM1 gene: a pilot investigation. Alcoholism Clinical and Experimental Research, *34*(8), 1479-1487.
45. **Ray, L.A.**, Krull, J.L., Leggio, L. (2010). The effects of naltrexone among alcohol non-abstainers: Results from the COMBINE Study. Frontiers in Psychiatry, *10*:3389.
46. Leventhal, A., Brightman, M., Ameringer, K.J., Greenberg, J., Mickens, L., **Ray, L.A.**, & Sussman, S. (2010). Anhedonia associated with stimulant use and dependence in a population-based sample of American adults. Experimental and Clinical Psychopharmacology, *18*(6), 562-569.
47. **Ray, L.A.** (2011). Stress-induced and cue-induced craving for alcohol in heavy drinkers: Preliminary evidence of genetic moderation by the OPRM1 and CRH-BP Genes. Alcoholism Clinical and Experimental Research, *35*(1), 166-174.
48. **Ray, L.A.**, Hart, E., Chin, P.F. (2011). Self-rating of the effects of alcohol (SRE): Predictive utility and reliability across interview and self-report administrations. Addictive Behaviors, *36*(3), 241-3.
49. **Ray, L.A.** Primack, J., Young, D., Chelminski, I., & Zimmerman, M. (2011). Treatment seeking men with and without substance use disorders. Psychology of Men and Masculinity, *12*(2), 158-165.
50. **Ray, L.A.**, Hart, E., Chelminski, I., Young, D., & Zimmerman, M. (2011). Clinical correlates of desire for treatment for current alcohol dependence in patients with a primary psychiatric disorder. American Journal of Drug and Alcohol Abuse, *37*(2), 105-110.
51. Ferriter, C. & **Ray, L.A.** (2011). Binge eating and binge drinking: an integrative review. Eating Behaviors, *12*(2), 99-107.
52. MacKillop, J., Amlung, M. T., Few, L.R., **Ray, L.A.**, Sweet, L.H., Munafo, M.R. (2011). Delayed reward discounting and addictive behavior: a meta-analysis. Psychopharmacology, *216*(3), 305-21.
53. **Ray, L.A.**, Chin, P.F., Heydari, A., & Miotto, K. (2011). A human laboratory study of the effects of quetiapine on subjective intoxication and alcohol craving. Psychopharmacology, *317*(3), 341-351.
54. Tartter, M. & **Ray, L.A.** (2011). The serotonin transporter polymorphism (5-HTTLPR) and alcohol problems in heavy drinkers: moderation by depressive symptoms. Frontiers in Psychiatry, *2*:49.

55. Ashenhurst, J., Jentsch, J.D., & **Ray, L.A.** (2011). Risk-taking and alcohol use disorders symptomatology in a clinical sample. Experimental and Clinical Psychopharmacology, *19*(5):361-70.
56. Heinzerling, K.G., McCracken, J.T., Swanson, A.N., **Ray, L.A.**, Shoptaw, S.J. (2012). COMT Val158Met, BDNF Val66Met, and OPRM1 Asn40Asp and Methamphetamine Dependence Treatment Response: Preliminary Investigation. Journal of Clinical Psychopharmacology, *32*(1):135-137.
57. Moallem, N. & **Ray, L.A.** (2012). The effects of quetiapine on response inhibition in alcohol dependent patients: a placebo-controlled pilot study. Pharmacology, Biochemistry, and Behavior, *100*(3):490-493.
58. **Ray, L.A.**, Courtney, K.E., Bujarski, S., & Squeglia, L.M. (2012). Pharmacogenetics of alcoholism: a clinical neuroscience perspective. Pharmacogenomics, *13*(2):129-132.
59. **Ray, L.A.**, Bujarski, S., Chin, P.F., & Miotto, K. (2012). Pharmacogenetics of naltrexone in Asian Americans: A randomized placebo-controlled laboratory study. Neuropsychopharmacology, *37*(2):445-455.
60. **Ray, L. A.**, Barr, C.S., Blendy, J.A., Oslin, D., Goldman, D., & Anton, R.F. (2012). The role of the Asn40Asp polymorphism of the mu opioid receptor (OPRM1) gene on alcoholism etiology and treatment: a critical review. Alcoholism Clinical and Experimental Research, *36*(3):385-394.
61. Courtney, K.E., Arellano, R., Barkley-Levenson, E., Gálvan, A., Poldrack, R.A., MacKillop, J., Jentsch, J.D., & **Ray, L.A.** (2012). The relationship between measures of impulsivity and alcohol misuse: an integrative structural equation modeling approach. Alcoholism Clinical and Experimental Research, *36*(6): 923-31.
62. Leventhal, A.M., **Ray, L.A.**, Rhee, S.H., & Unger, J.B. (2012). Genetic and environmental influences on the association between depressive symptom dimensions and smoking initiation among Chinese adolescent twins. Nicotine & Tobacco Research, *14*(5): 559-68.
63. MacKillop, J., Amlung, M., Wier, L., David, S., **Ray, L.A.**, Bickell, W., & Sweet, L.H. (2012). The neuroeconomics of nicotine dependence: an fMRI study of delay discounting of monetary and cigarette rewards in smokers. Psychiatry Research, *202*(1): 20-29.
64. Plebani, J., **Ray, L.A.**, Morean, M.E., Corbin, W.R., MacKillop, J., Amlung, M., King, A.C. (2012). Laboratory paradigms in alcohol research: a critical review. Alcoholism Clinical and Experimental Research, *36*(6):972-83
65. Bujarski, S., MacKillop, J., & **Ray, L.A.** (2012). Understanding naltrexone mechanism of action and pharmacogenetics via behavioral economics: a preliminary study. Experimental and Clinical Psychopharmacology, *20*(3): 181-190.
66. Moallem, N. & **Ray, L.A.** (2012). Dimensions of impulsivity among heavy drinkers, smokers, and heavy drinking smokers: singular and combined effects. Addictive Behaviors, *37*(7): 871-874.
67. Tartter, M. & **Ray, L.A.** (2012). A prospective study of laboratory-based stress and alcohol craving in heavy drinkers. Pharmacology, Biochemistry, and Behavior, *101*(4): 625-631.
68. **Ray, L. A.** (2012). Clinical neuroscience of addiction: Applications to psychological science and practice. Clinical Psychology: Science and Practice, *19*(2), 154-166.
69. Ashenhurst, J.R., Bujarski, S., & **Ray, L.A.** (2012). Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol. Pharmacology, Biochemistry, and Behavior, *103*(2), 253-259.
70. Bholat, M.A., **Ray, L.A.**, Brensilver, M., Ling, K., & Shoptaw, S. (2012). Integration of behavioral medicine in primary care. Primary Care, *39*(4), 605-614.
71. Miranda, R. Jr., Reynolds, E., **Ray, L.A.**, Justus, A., Knopik, V.S., McGeary, J., & Meyerson, L.A. (2013). Preliminary evidence for a gene-environment interaction in predicting alcohol use disorders in adolescents. Alcoholism: Clinical and Experimental Research, *37*(2), 325-331
72. **Ray, L.A.**, Bujarski, S., MacKillop, J., Courtney, K.E., Monti, P.M., & Miotto, K. (2013). Sensitivity to alcohol among alcohol dependent individuals: the effects of the mu opioid receptor (OPRM1) gene and alcoholism severity. Alcoholism: Clinical and Experimental Research, *37*(1), E116-E124
73. Bujarski, S., O'Malley, S., Lunny, K.N., & **Ray, L.A.** (2013). The effects of drinking goal on treatment outcome for alcoholism. Journal of Consulting and Clinical Psychology, *(81)*1, 13-22

74. Courtney, K.E., Ghahremani, D., & **Ray, L.A.** (2013). Fronto-striatal functional connectivity during response inhibition in alcohol dependence. *Addiction Biology*, (18)3, 593-604
75. **Ray, L.A.**, Lunny, K., Bujarski, S., Moallem, N., Krull, J.L., & Miotto, K. (2013). The effects of varenicline on stress-induced and cue-induced craving for cigarettes. *Drug and Alcohol Dependence*, 131(1-2), 136-142.
76. Courtney, K.E., Ashenhurst, J., Bacio, G., Moallem, N., Bujarski, S., Hartwell, E., & **Ray, L.A.** (2013). Subjective response to alcohol and alcohol craving: Validation of the Desires for Alcohol Questionnaire (DAQ) in the human lab. *Journal of Studies on Alcohol and Drugs*, 74(5), 797-802.
77. **Ray, L.A.**, Sehl, M., Bujarski, S., Hutchison, K.E., Blaine, S., & Enoch, M. (2013). The CRHR1 gene, trauma exposure, and alcoholism risk: A test of G × E effects. *Genes, Brain & Behavior*, 12(4), 361-9.
78. Hartwell, E. & **Ray, L.A.** (2013). Sex moderates stress reactivity in heavy drinkers. *Addictive Behaviors*, 38(11), 2643-6.
79. Moallem, N.R., Courtney, K.E., Bacio, G.A., & **Ray, L.A.** (2013). Modeling alcohol use disorder severity: An integrative structural equation modeling approach. *Frontiers in Psychiatry*, 4:75.
80. Lin, J.C., Karno, M.P., Grella, C.E., **Ray, L.A.**, Liao, D.H., & Moore, A.A. (2013) Psychiatric correlates of alcohol and tobacco use disorders in U.S. adults aged 65 and older: Results from the 2001-2002 National Epidemiologic Survey of Alcohol and Related Conditions. *American Journal of Geriatric Psychiatry*, S1064-7481(13)00308-4.
81. **Ray, L.A.**, Courtney, K., Hutchison, K.E., MacKillop, J., Galvan, A., & Ghahremani, D. (2013). Initial evidence that OPRM1 genotype moderates ventral and dorsal striatum functional connectivity during alcohol cues. *Alcoholism: Clinical and Experimental Research*, 37 Suppl 1, E116-24.
82. Miranda Jr., R., **Ray, L.A.**, Blanchard, A., Reynolds, E.K., Monti, P.M., Chun, T., Justus, A., Swift, R. M., Tidey, J., Gwaltney, C.J., & Ramirez, J. (2014). Effects of naltrexone on adolescent alcohol cue-reactivity and sensitivity: An initial randomized trial. *Addiction Biology*, 19(5), 941-954.
83. Courtney, K. & **Ray, L.A.** (2014). Subjective response to alcohol in the lab predicts neural response to alcohol cues. *Journal of Studies on Alcohol and Drugs*, 75(1), 124-35.
84. Bacio, G.A., Lunny, K.F., Webb, J.N., & **Ray, L.A.** (2014). Alcohol use following an alcohol challenge and a brief intervention among alcohol-dependent individuals. *American Journal on Addiction*, 23(1), 96-101.
85. Bacio, G.A., Moore, A., Karno, M., & **Ray, L.A.** (2014). Determinants of problem drinking and depression among Latino day laborers. *Substance Use & Misuse*, 49(8), 1039-1048.
86. Miranda Jr., R., Monti, P.M., **Ray, L.A.**, Treloar, H.R., Reynolds, E.K., Ramirez, J., Chun, T., Gwaltney, C.J., Justus, A., Tidey, J., Blanchard, A., & Magill, M. (2014). Characterizing subjective responses to alcohol among adolescent problem drinkers. *Journal of Abnormal Psychology*, 123(1), 117-29.
87. **Ray, L.A.**, Bujarski, S., Squeglia, L.M., Ashenhurst, J.R., & Anton, R. (2014). Interactive effects of OPRM1 and DAT1 genetic variation on subjective responses to alcohol. *Alcohol & Alcoholism*, 49(3), 261-270.
88. DeMartini, K.S., Devine, E., DiClemente, C., Martin, D., **Ray, L.A.**, & O'Malley, S.S. (2014). Predictors of pre-treatment commitment to abstinence: Results from the COMBINE Trial. *Journal of Studies on Alcohol and Drugs*, 75(3), 438-446.
89. MacKillop, J., Amlung, M.T., Acker, J., Gray, J.C., Brown, C.L., Murphy, J.G., **Ray, L.A.**, & Sweet, L.H. (2014). The neuroeconomics of alcohol demand: an initial investigation of the neural correlates of alcohol cost-benefit decision making in heavy drinking men. *Neuropsychopharmacology*, 39(8), 1988-1995.
90. Roche, D., Bujarski, S., Moallem, N., Guzman, I., Shapiro, J., & **Ray, L.A.** (2014). Predictors of smoking lapse in a human laboratory paradigm. *Psychopharmacology*, 231(14), 2889-2897.
91. Courtney, K., Ghahremani, D., London, E.D., & **Ray, L.A.** (2014). The association between cue reactivity in the precuneus and level of dependence on nicotine and alcohol. *Drug and Alcohol Dependence*, 141, 21-26.

92. Bujarski, S. & **Ray, L.A.** (2014). Subjective response to alcohol and associated craving in heavy drinkers vs. alcohol dependents: An examination of Koob's allostatic model in humans. *Drug and Alcohol Dependence*, *140*, 161-167.
93. Ashenhurst, J.R., Bujarski, S., Jentsch, J.D., & **Ray, L.A.** (2014). Modeling behavioral reactivity to losses and rewards on the Balloon Analogue Risk Task (BART): Moderation by alcohol problem severity. *Experimental and Clinical Psychopharmacology*, *22*(4), 298-306
94. **Ray, L.A.**, Courtney, K., Ghahremani, D., Miotto, K., Brody, A., & London, E.D. (2014). Varenicline, low dose naltrexone, and their combination for heavy drinking smokers: Human laboratory findings. *Psychopharmacology*, *231*(19), 3843-53
95. **Ray, L.A.**, Roche, D., Heinzerling, K., & Shoptaw, S. (2014). Opportunities for the development of neuroimmune therapies in addiction. *International Review of Neurobiology*, *118*, 381-401.
96. Sujan, A. C., Humphreys, K. L., **Ray, L. A.**, & Lee, S. S. (2014). Differential association of child abuse with self-reported versus laboratory-based impulsivity and risk-taking in young adulthood. *Child Maltreatment*, *19*(3-4), 145-155.
97. Bacio, G.A., Guzman, I.Y., Shapiro, J.R., & **Ray, L.A.** (2014). Differences in quit attempts between Black and White daily smokers: the role of smoking motives. *Addictive Behaviors*, *39*(12), 1769-1772.
98. Bujarski, S., Roche, D., Lunny, K., Moallem, N.R., Courtney, K.E., Allen, V., Hartwell, E., Leventhal, A., Rohrbaugh, T., & **Ray, L.A.** (2014). The relationship between methamphetamine and alcohol use in a community sample of methamphetamine users. *Drug and Alcohol Dependence*, *142*, 127-132.
99. Courtney, K.E. & **Ray, L.A.** (2014). Methamphetamine: An update on epidemiology, pharmacology, clinical phenomenology, and treatment literature. *Drug and Alcohol Dependence*, *143*, 11-21.
100. Bujarski, S. & **Ray, L.A.** (2014). Negative affect is associated with alcohol, but not cigarette use in heavy drinking smokers. *Addictive Behaviors*, *39*(12), 1723-1729.
101. Owens, M., **Ray, L.A.**, & MacKillop, J. (2015). Behavioral economic analysis of stress effects on acute motivation for alcohol. *Journal of the Experimental Analysis of Behavior*, *103*(1), 77-86.
102. Bujarski, S., Roche, D.J.O., Sheets, E.S., Krull, J.L., Guzman, I., & **Ray, L.A.** (2015). Modeling naturalistic craving, withdrawal, and affect during early nicotine abstinence: a pilot EMA study. *Experimental and Clinical Psychopharmacology*, *23*(2), 81-89.
103. Sheets, E. S., Bujarski, S., Leventhal, A. M., & **Ray, L. A.** (2015). Emotion differentiation and intensity during acute tobacco abstinence: A comparison of heavy and light smokers. *Addictive Behaviors*, *47*, 70-73.
104. **Ray, L.A.**, Courtney, K., Ghahremani, D., Miotto, K., Brody, A. & London, E.D. (2015). Varenicline, naltrexone, and their combination for heavy drinking smokers: Preliminary neuroimaging findings. *American Journal of Drug and Alcohol Abuse*, *41*(1), 35-44.
105. Roche D.J.O., **Ray L.A.** (2015). Subjective response as a consideration in the pharmacogenetics of alcoholism treatment. *Pharmacogenomics*, *16*(7), 721-36.
106. Roche, D.J.O., Bujarski, S., Hartwell, E., Green, R., & **Ray, L.A.** (2015). Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy drinking smokers. *Pharmacology, Biochemistry, and Behavior*, *134*, 92-98.
107. **Ray, L.A.**, Bujarski, S.E., Courtney, K.E., Moallem, N.R., Lunny, K., Roche, D.J.O., Leventhal, A., Shoptaw, S., Heinzerling, K., London, E.D., & Miotto, K. (2015). The effects of naltrexone on subjective response to methamphetamine in a clinical sample: A double-blind, placebo-controlled, laboratory study. *Neuropsychopharmacology*, *40*(10), 2347-56.
108. Allen, V., Myers, H.F., & **Ray, L.A.** (2015). The association between alcohol consumption and condom use: Considering correlates of HIV risk among Black men who have sex with men. *AIDS & Behavior*, *19*(9), 1689-1700.
109. Bujarski, S., Hutchison, K.E., Roche, D.J.O., & **Ray, L.A.** (2015). Factor structure of subjective responses to alcohol in light and heavy drinkers. *Alcoholism: Clinical and Experimental Research*, *39*(7), 1193-1202.

110. Bidwell, L.C., Knopik, V.S., Audrain-McGovern, J., Glynn, T.R., Spillane, N.S., **Ray, L.A.**, Riggs, N.R., Guillot, C., Pang, R.D., & Leventhal, A.M. (2015). Novelty seeking as a phenotypic marker of adolescent substance use. *Substance Abuse: Research and Treatment*, *9*(Suppl 1), 1-10.
111. Courtney, K.E., Ghahremani, D.G., & **Ray, L.A.** (2015). The effect of alcohol priming on neural markers of alcohol cue-reactivity. *American Journal of Drug and Alcohol Abuse*, *41*(4), 300-308.
112. Bujarski, S.E., Lau, A., Lee, S., & **Ray, L.A.** (2015). Genetic and environmental predictors of alcohol use in Asian American young adults. *Journal of Studies on Alcohol and Drugs*, *76*(5), 690-699.
113. Yardley, M.M., Mirbaba, M.M., & **Ray, L.A.** (2015). Pharmacological options for smoking cessation in heavy-drinking smokers. *CNS Drugs*, *29*(10), 833-845.
114. Courtney, K.E., Schacht, J.P., Hutchison, K.E., Roche, D.J.O., & **Ray, L.A.** (2015). Neural substrates of cue-reactivity: Association with treatment outcome and relapse. *Addiction Biology*, *21*(1), 3-22.
115. Hartwell, E.E., Bujarski, S., Glasner-Edwards, S., & **Ray, L.A.** (2015). The association of alcoholism severity with sleep quality in problem alcohol users. *Alcohol & Alcoholism*, *50*(5), 536-541.
116. **Ray, L.A.**, Bujarski, S., & Roche, D.J.O. (2016). Subjective response to alcohol as a research domain criterion. *Alcoholism: Clinical and Experimental Research*, *40*(1), 6-17.
117. Moore, A.A., Karno, M.P., **Ray, L.A.**, Ramirez, K., Barenstein, V., Portillo, M., Rizo, P., Borok, J., Liao, D.H., Barron, J., Del Pino, H.E., Valenzuela, A., Barry, K.L. (2016). Development and preliminary testing of a promotora-delivered, Spanish language, counseling intervention for unhealthy drinking among male, Latino day laborers. *Journal of Substance Abuse Treatment*, *62*, 96-101.
118. Inagaki, T.K., **Ray, L.A.**, Irwin, M.R., Way, B.M., Eisenberger, N.I. (2016). Opioids and social bonding: Naltrexone reduces feelings of social connection. *Social Cognitive and Affective Neuroscience*, *11*(5), 728-735.
119. Squeglia, L. M., Brammer, W. A., **Ray, L. A.**, & Lee, S. S. (2016). Attention-deficit/hyperactivity disorder (ADHD) symptoms predict alcohol expectancy development. *Journal of Child and Adolescent Substance Abuse*, *25*(2), 159-179.
120. Courtney, K.E., & **Ray, L.A.** (2016). Clinical neuroscience of amphetamine-type stimulants: From basic science to treatment development. *Progress in Brain Research*, *223*, 295-310.
121. Bacio, G.A. & **Ray, L.A.** (2016). Patterns of drinking initiation among Latino youths: Cognitive and contextual explanations of the immigrant paradox. *Journal of Child & Adolescent Substance Abuse*, *25*(6), 546-556.
122. Roche, D.J.O., **Ray, L.A.**, Yardley, M.M., & King, A.C. (2016). Current insights into the mechanisms and treatments for heavy-drinking cigarette smokers. *Current Addiction Reports*, *3*(1), 125-137.
123. Roche, D.J.O., Lunny, K.F., Yardley, M.M., Louie, S.G., Davies, D.L., Miotto K., & **Ray L.A.** (2016). A Pilot study of the safety and initial efficacy of ivermectin for the treatment of alcohol use disorder. *Alcoholism: Clinical and Experimental Research*, *40*(6), 1312-1320.
124. Green, R., Bujarski, S., Roche, D.J.O., & **Ray, L.A.** (2016). Relationship between negative affect and smoking topography in heavy drinking smokers. *Addictive Behaviors*, *61*, 53-57.
125. Chung, T., Noronha, A., Carroll, K.M., Potenza, M.N., Hutchison, K., Calhoun, V.D., Gabrieli, J.D.E., Morgenstern, J., Nixon, S.J., Wexler, B.E., Brewer, J., **Ray, L.A.**, Filbey, F., Strauman, T.J., Kober, H., & Feldstein Ewing, S.W. (2016). Brain mechanisms of change in addiction treatment: Models, methods, and emerging findings. *Current Addiction Reports*, *3*(3), 332-342.
126. Bujarski, S. & **Ray, L.A.** (2016). Experimental psychopathology paradigms for alcohol use disorder: Applications for translational research. *Behaviour Research and Therapy*, *86*, 11-22.
127. Courtney, K.E., Ghahremani, D.G., & **Ray, L.A.** (2016). The effects of pharmacological opioid blockade on neural measures of drug cue-reactivity in humans. *Neuropsychopharmacology*, *41*(12), 2872-2881.
128. Hartwell, E.E., Moallem, N.R., Courtney, K.E., Glasner-Edwards, S., & **Ray, L.A.** (2016). Sex differences in the association between internalizing symptoms and craving in methamphetamine users. *Journal of Addiction Medicine*, *10*(6), 395-401.

129. Cservenka, A. & **Ray, L.A.** (2017). Self-reported attentional and motor impulsivity are related to age at first methamphetamine use. Addictive Behaviors, 65, 7-12.
130. Bujarski, S.E., Hutchison, K.E., Prause, N., & **Ray, L.A.** (2017). Functional significance of subjective response to alcohol across levels of alcohol exposure. Addiction Biology, 22(1), 235-245.
131. Westman, J., Bujarski, S.E., & **Ray, L.A.** (2017). Impulsivity moderates subjective responses to alcohol in alcohol dependent individuals. Alcohol & Alcoholism, 52(2), 249-255.
132. Cummings, J.R., **Ray, L.A.**, & Tomiyama, A.J. (2017). Food-alcohol competition: As young females eat more food, do they drink less alcohol? Journal of Health Psychology, 22(5), 674-683.
133. Yardley, M., & **Ray, L.A.** (2017). Medications development for the treatment of alcohol use disorder: Insights into the predictive value of animal paradigms and human laboratory models. Addiction Biology, 22(3), 581-615.
134. Bullock, K., Cservenka, A., & **Ray, L.A.** (2017). Severity of alcohol dependence is negatively related to hypothalamic and prefrontal cortical gray matter density in heavy drinking smokers. American Journal of Drug and Alcohol Abuse, 43(3), 281-290.
135. Lim, A., Cservenka, A., & **Ray, L.A.** (2017). Effects of alcohol dependence severity on neural correlates of delay discounting. Alcohol & Alcoholism, 52(4), 506-515.
136. Roche, D. J., Worley, M. J., Courtney, K. E., Bujarski, S., London, E. D., Shoptaw, S., & Ray, L. A. (2017). Naltrexone moderates the relationship between cue-induced craving and subjective response to methamphetamine in individuals with methamphetamine use disorder. Psychopharmacology, 234(13), 1997-2007.
137. **Ray, L.A.**, Bujarski, S.E., Shoptaw, S., Roche, D.J.O., Heinzerling, K., & Miotto, K. (2017). Development of the neuroimmune modulator ibudilast for the treatment of alcoholism: A randomized, placebo-controlled, human laboratory trial. Neuropsychopharmacology, 42(9), 1776-1788.
138. Bello, M.S., Pang, R.D., Chasson, G.S., **Ray, L.A.**, & Leventhal, A.M. (2017). Obsessive-compulsive symptoms and negative affect during tobacco withdrawal in a non-clinical sample of African American smokers. Journal of Anxiety Disorders, 48, 78-86.
139. Cservenka, A., Yardley, M.M., & **Ray, L.A.** (2017). Review: Pharmacogenetics of alcoholism treatment: Implications of ethnic diversity. American Journal on Addictions, 26(5), 516-525.
140. **Ray, L. A.**, Bujarski, S., Yardley, M. M., Roche, D. J., & Hartwell, E. E. (2017). Differences between treatment-seeking and non-treatment-seeking participants in medication studies for alcoholism: do they matter? The American Journal of Drug and Alcohol Abuse, 43(6), 703-710.
141. Cservenka, A., Courtney, K. E., Ghahremani, D. G., Hutchison, K. E., & **Ray, L. A.** (2017). Development, initial testing and challenges of an ecologically valid reward prediction error fMRI task for alcoholism. Alcohol and Alcoholism, 52(5), 617-624.
142. Hartwell, E. & **Ray, L.A.** (2017). Craving as a DSM-5 symptom of alcohol use disorder in non-treatment seekers. Alcohol and Alcoholism, 53(3), 235-240.
143. Bujarski, S., Lim, A.C., & **Ray, L.A.** (2018). Prevalence, Causes, and Treatment of Substance Use Disorders: A PRIMER. The Judges' Journal, 57(1), 10-15.
144. Garneau, H. C., Venegas, A., Rawson, R., Ray, L. A., & Glasner, S. (2018). Barriers to initiation of extended release naltrexone among HIV-infected adults with alcohol use disorders. Journal of Substance Abuse Treatment, 85, 34-37.
145. **Ray, L.A.**, Green, R., Roche, D.J.O., Bujarski, S., Hartwell, E., Lim, A., Rohrbaugh, T., Ghahremani, D., Hutchison, K.E., Miotto, K. (2018). Pharmacogenetic effects of naltrexone in individuals of East Asian descent: Human laboratory findings. Alcoholism: Clinical and Experimental Research, 42(3), 613-623.
146. Moallem, N.R., Courtney, K.E., & **Ray, L.A.** (2018). The relationship between impulsivity and methamphetamine use severity in a community sample. Drug and Alcohol Dependence, 187, 1-7.
147. Green, R. & **Ray, L.A.** (2018). Effects of varenicline on subjective craving and relative reinforcing value of cigarettes. Drug and Alcohol Dependence, 188, 53-59.
148. Hartwell, E. & **Ray, L.A.** (2018). Relationship between tonic and phasic craving for alcohol. Addictive Behavior Reports, 7, 71-74.

149. Bujarski, S., Jentsch, J.D., Roche, D.J.O., Ramchandani, V.A., Miotto, K., & **Ray, L.A.** (2018) Differences in the subjective and motivational properties of alcohol across alcohol use disorder severity: Application of a novel translational paradigm in a clinical sample. *Neuropsychopharmacology*, 43(9), 1891-1899.
150. **Ray, L.A.** & Roche, D.J.O. (2018). Neurobiology of craving: Current findings and new directions. *Current Addiction Reports*, 5(2), 102-109.
151. Cummings, J.R., Tomiyama, J., & **Ray, L.A.** (2018). Does the neuroimmune modulator ibudilast alter food craving? Results in a sample with alcohol use disorder. *Journal of Addiction Medicine*, 12(5), 410-417.
152. Allen, V.C., **Ray, L.A.**, & Myers, H.F. (2018). The sexual health consequences of alcohol consumption among Black gay and bisexual men. *Alcoholism: Clinical & Experimental Research*, 42(8), 1548-1555.
153. **Ray, L.A.**, Bujarski, S., Roche, D.J.O., & Magill, M. (2018). Overcoming the “Valley of Death” in medications development for alcohol use disorder. *Alcoholism: Clinical & Experimental Research*, 42(9), 1612-1622.
154. Bello, M.S., McBeth, J.F., Ditre, J.W., Kirkpatrick, M.G., **Ray, L.A.**, Dunn, K.E., & Leventhal, A.M. (2018). Pain as a predictor and consequence of tobacco abstinence effects amongst African American smokers. *Journal of Abnormal Psychology*, 127(7), 683-694.
155. Lim, A.C., Courtney, K.E., Moallem, N.R., Allen, V.C., Leventhal, A.M., & **Ray, L.A.** (2018). A brief smoking cessation intervention for heavy drinking smokers: Treatment feasibility and acceptability. *Frontiers in Psychiatry*, 9, 362.
156. Lim, A.C., Roche, D.J.O., & **Ray, L.A.** (2018). Distress tolerance and craving for cigarettes among heavy drinking smokers. *Journal of Studies on Alcohol and Drugs*, 79(6), 918-928.
157. **Ray, L.A.**, Bujarski, S., Grodin, E., Hartwell, E., Green, R., Venegas, A., Lim, A.C., Gillis, A., & Miotto, K. (2019). State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. *American Journal of Drug and Alcohol Abuse*, 45(2), 124-140.
158. Falk, D., Ryan, M.L., Fertig, J.B., Devine, E.G., Cruz, R., Brown, S., Burns, H., Salloum, I.M., Newport, J., Mendelson, J., Galloway, G., Kampman, K., Brooks, C., Green, A., Brunette, M., Rosenthal, R.N., Dunn, K.E., Strain, E.C., **Ray, L.A.**, Shoptaw, S., Ait-Doud, N., Gunderson, E.W., Ransom, J., Scott, C., Leggio, L., Caras, S., Mason, B.J., and Littlen, R.Z., for the National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group (NCIG) Study Group (2019). Gabapentin enacarbil extended-release for alcohol use disorder: A randomized, double-blind, placebo-controlled, multisite trial assessing efficacy and safety. *Alcoholism: Clinical & Experimental Research*, 43(1), 158-169.
159. Green, R., Bujarski, S., Lim, A.C., Venegas, A., & **Ray, L.A.** (2019). Naltrexone and alcohol effects on craving for cigarettes in heavy drinking smokers. *Experimental and Clinical Psychopharmacology*, 27(3), 257-264.
160. Grodin, E.N., **Ray, L.A.**, MacKillop, J., Lim, A.C., & Karno, M.P. (2019). Elucidating the effect of a brief drinking intervention using neuroimaging: A preliminary study. *Alcoholism: Clinical & Experimental Research*, 43(2), 367-377.
161. Grodin, E., Courtney, K., & **Ray, L.A.** (2019). Drug-induced craving for methamphetamine is associated with neural methamphetamine cue reactivity. *Journal of Studies on Alcohol and Drugs*, 80(2), 245-251.
162. Green, R., Grodin, E., Lim, A.C., Venegas, A., Bujarski, S., Krull, J., & **Ray, L.A.** (2019). The interplay between subjective response to alcohol, craving, and alcohol self-administration in the human laboratory. *Alcoholism: Clinical & Experimental Research*, 43(5), 907-915.
163. Roche, D.J.O., Bujarski, S., Green, R., Hartwell, E., Leventhal, A., & **Ray, L.A.** (2019). Alcohol, tobacco, and marijuana consumption is associated with increased odds of same-day substance co- and tri-use. *Drug and Alcohol Dependence*, 200, 40-49.
164. Lim, A., Ghahremani, D., Grodin, E., Green, R., Bujarski, S., Hartwell, E., Courtney, K., Hutchison, K.E., Miotto, K., & **Ray, L.A.** (2019). Neuroimaging findings from an experimental pharmacology trial of naltrexone in heavy drinkers of East Asian descent. *Drug and Alcohol Dependence*, 200, 181-190.

165. Grodin, E.N., Lim, A.C., MacKillop, J., Karno, M.P., & **Ray, L.A.** (2019). An examination of motivation to change and neural alcohol cue reactivity following a brief intervention. Frontiers in Psychiatry, *10*, 408.
166. Cortland, C., Shapiro, J., Guzman, I., & **Ray, L.A.** (2019). The ironic effects of stigmatizing smoking: Combining stereotype threat theory with behavioral pharmacology. Addiction, *114*(10), 1842-4848.
167. Liu, Y., van den Wildenberg, W.P.M., de Graaf, Y., Ames, S.L., Baldacchino, A., Bø, R., Cadaveira, F., Campanella, S., Christiansen, P., Claus, E.D., Colzato, L.S., Filbey, F.M., Foxe, J.J., Garavan, H., Hendershot, C.S., Hester, R., Jester, J.M., Karoly, H.C., Kräplin, A., Kreusch, F., Landrø, N.I., Little, M., Steins-Loeber, S., London, E.D., López-Caneda, E., Lubman, D.I., Luijten, M., Marczinski, C.A., Metrik, J., Montgomery, C., Papachristou, H., Park, S.M., Paz, A.L., Petit, G., Prisciandaro, J.J., Quednow, B.B., **Ray, L.A.**, Roberts, C.A., Roberts, G.M.P., de Ruiter, M.B., Rupp, C.I., Steele, V.R., Sun, D., Takagi, M., Tapert, S.F., van Holst, R., Verdejo-Garcia, A., Vonmoos, M., Wojnar, M., Yao, Y., Yücel, M., Zack, M., Zucker, R.A., Huizenga, H.M., Wiers, R.W. (2019). Is (poly-) substance use associated with impaired inhibitory control? A mega-analysis controlling for confounders. Neuroscience & Biobehavioral Reviews, *105*, 288-304.
168. Hartwell, E., Bujarski, S., Green, R., & **Ray, L.A.** (2019). Convergence between the Penn Alcohol Craving Scale and diagnostic interview for the assessment of alcohol craving. Addictive Behaviors Reports, *10*, 100198.
169. Venegas, A. & **Ray, L.A.** (2019). Comparing alcohol cue-reactivity in treatment-seekers versus non treatment-seekers with alcohol use disorder. American Journal of Drug and Alcohol Abuse, *46*(1), 131-138.
170. **Ray, L.A.**, Green, R., Roche, D.J.L., Magill, M., & Bujarski, S. (2019). Naltrexone effects on subjective responses to alcohol: A systematic review and meta-analysis. Addiction Biology, *24*(6), 1138-1152.
171. Grodin, E.N. & **Ray, L.A.** (2019). The use of fMRI to test pharmacotherapies for alcohol use disorder: A systematic review. Alcoholism: Clinical & Experimental Research, *43*(10), 2038-2056.
172. Grodin, E.N. Bujarski, S.E., Nieto, S., Jentsch, J.D., & **Ray, L.A.** (2019). Reward, relief, and habit drinking: Initial validation of a brief assessment tool. Alcohol & Alcoholism, *54*(6), 574-583.
173. Magill, M., **Ray, L.A.**, Kiluk, B., Hoadley, A., Bernestein, M., Tonigan, J.S., & Carroll, K. (2019). A meta-analysis of Cognitive-Behavioral Therapy for alcohol or other drug use disorders treatment efficacy by contrast condition. Journal of Consulting & Clinical Psychology, *87*(12), 1093-1105.
174. Kiluk, B., **Ray, L.A.**, Walthers, J., Bernstein, M., Tonigan, J.S., & Magill, M. (2019). Technology-delivered Cognitive-Behavioral Therapy for alcohol use: A meta-analysis. Alcoholism: Clinical & Experimental Research, *43*(11), 2285-2295.
175. Burnette, E. Grodin, E.N., Lim, A.C., McKillop, J., Karno, M.P., & **Ray, L.A.** (2019). Association between impulsivity and neural activation to alcohol cues in heavy drinkers. Psychiatry Research: Neuroimaging, *293*, 110986.
176. Cummings, J., Nooteboom, P., **Ray, L.A.**, & Tomiyama, J.A. (2020). Acute effect of eating sweets on alcohol cravings in a sample with at-risk drinking. Annals of Behavioral Medicine, *54*(2), 132-138.
177. Cummings, J. R., Gearhardt, A. N., **Ray, L. A.**, Choi, A. K., & Tomiyama, A. J. (2020). Experimental and observational studies on alcohol use and dietary intake: A systematic review. Obesity Reviews, *21*(2), e12950.
178. **Ray, L.A.**, Du, H., Grodin, E., Bujarski, S., Meredith, L., Ho, D., Nieto, S., & Wassum, K. (2020). Capturing habitualness of drinking and smoking behavior in humans. Drug and Alcohol Dependence, *207*:107738.
179. Grodin, E.N., Nguyen, X., Ho, D., Bujarski, S., & **Ray, L.A.** (2020). Sensitivity and specificity of a commercial urinary ethyl glucuronide (EtG) test in heavy drinkers. Addictive Behaviors Reports, *11*: 100249.

180. Glasner, S. Choron Garneau, H., Ang, A., **Ray, L.A.**, Venegas, A., Rawson, R., & Kalichman, S. (2020). Preliminary efficacy of a cognitive behavioral therapy text messaging intervention targeting alcohol use and antiretroviral therapy adherence: A randomized clinical trial. *PLoS One*, *15*(3): e0229557.
181. **Ray, L.A.**, Meredith, L., Kiluk, B.D., Walthers, J., Carroll, K.M., & Magill, M. (2020). Combined pharmacotherapy and cognitive behavioral therapies for adults with alcohol or substance use disorders: A systematic review and meta-analysis. *JAMA Network Open*, *3*(6): e208279.
182. Venegas, A., Meredith, L.R., Cooper, Z.D., Towns, B., & **Ray, L.A.** (2020). Inclusion of cannabis users in alcohol research samples: Screening in, screening out, and implications. *Alcohol & Alcoholism*, *55*(4), 416-423.
183. Lim, A.C., Green, R., Grodin, E.N., Venegas, A., Meredith, L.R., Donato, S., Burnette, E., & **Ray, L.A.** (2020). Alcohol cue-induced ventral striatum activity predicts subsequent alcohol self-administration. *Alcoholism: Clinical & Experimental Research*, *44*(6), 1224-1233.
184. Grodin, E.N., Green, R., & **Ray, L.A.** (2020). An exploratory factor analysis of the stimulant, sedative, and affective responses to alcohol. *Alcoholism: Clinical & Experimental Research*, *44*(11), 2298-2306.
185. Aguirre, C.G., Stolyarova, A., Das, K., Kolli, S., Marty, V., **Ray, L.A.**, Spigelman, I., & Izquierdo, A. (2020). Sex-dependent effects of Chronic intermittent voluntary alcohol consumption on attentional, not motivational, measures during probabilistic learning and reversal. *PLoS One*, *15*(6): e0234729.
186. Magill, M., Tonigan, J.S., Kiluk, B., **Ray, L.A.**, Walthers, J., Carroll, K. (2020). The search for mechanisms of Cognitive Behavioral Therapy for alcohol or other drug use disorders: A systematic review. *Behaviour Research and Therapy*, *131*:103648.
187. Nieto, S.J., Grodin, E.N., & **Ray, L.A.** (2020). On the path towards personalized medicine: Implications of pharmacogenetics studies of alcohol use disorder medications. *Expert Review of Precision Medicine and Drug Development*, *5*(1), 43-54.
188. Ho, D., Towns, B.T., Grodin, E.N., & **Ray, L.A.** (2020). A novel human laboratory model for screening medications for alcohol use disorder. *Trials*, *21*(1), 947.
189. Lim, A.C., Grodin, E.N., Green, R., Venegas, A., Meredith, L., Courtney, K.E., Moallem, N.R., Sayegh, P., London, E.D., & **Ray, L.A.** (2020). Executive function moderates naltrexone effects on methamphetamine-induced craving and subjective responses. *American Journal of Drug and Alcohol Abuse*, *46*(5), 565-576.
190. Kramer, J., Dick, D.M., King, A., **Ray, L.A.**, Sher, K.J., Vena, A., Vendruscolo, L.F., Acion, L. (2020). Mechanisms of alcohol addiction: bridging human and animal studies. *Alcohol & Alcoholism*, *55*(6), 603–607.
191. Meredith, L.R., Lim, A.C., & **Ray, L.A.** (2020). Neurocognitive performance in alcohol use disorder using the NIH toolbox: Role of severity and sex differences. *Drug and Alcohol Dependence*, *216*, 108269.
192. Burnette, E., Baskerville, W.A., Grodin, E., & **Ray, L.A.** (2020) Ibutilast for alcohol use disorder: Study protocol for a Phase II randomized clinical trial. *Trials*, *21*(1), 779.
193. Nieto, S., Green, R., MacKillop, J., & **Ray, L.A.** (2020). Intravenous alcohol administration selectively decreases elasticity of demand in individuals with alcohol use disorder. *Alcoholism: Clinical & Experimental Research*, *44*(11), 2336-2342.
194. Green, R., MacKillop, J., Hartwell, E., Lim, A., Baskerville, W., Karno, M., & **Ray, L.A.** (2021). Behavioral economic demand for alcohol and cigarettes in heavy drinking smokers: Evidence of asymmetric cross-commodity reinforcing value. *Nicotine & Tobacco Research*, *23*(4), 748-755.
195. **Ray, L.A.**, Grodin, E., Leggio, L., Bechtholt, A., Becker, H., Feldstein Ewing, S., Jentsch, J.D., King, A., Mason, B., O'Malley, S., MacKillop, J., Heilig, M., & Koob, G. (2021). The future of translational research in alcohol use disorder. *Addiction Biology*, *26*(2), e12903.
196. Grodin, E.N., Montoya, A.K., Bujarski, S., & **Ray, L.A.** (2021). Modeling motivation for alcohol in humans using traditional and machine learning approaches. *Addiction Biology*, *26*(3), e12949.
197. Bello, M.S., Liautaud, M.M., DeLaCerde, J.T., Pang, R.D., **Ray, L.A.**, Ahluwalia, J.S., & Leventhal, A.M. (2021). Association of Frequency of Perceived Exposure to Discrimination with Tobacco Withdrawal Symptoms and Smoking Lapse Behavior in African Americans. *Addiction*, *116*(4), 914-925.

198. Nieto, S.J., Green, R., Grodin, E.N., Cahill, C.M., & **Ray, L.A.** (2021). Pain catastrophizing predicts alcohol craving in heavy drinkers independent of pain intensity. *Drug and Alcohol Dependence*, *218*, 108368.
199. Burnette, E., Grodin, E.N., Schacht, J., & **Ray, L.A.** (2021). Clinical and neural correlates of reward and relief drinking. *Alcoholism: Clinical & Experimental Research*, *45*(1), 194-203.
200. Burnette, E., Grodin, E.N., Ghahremani, D.G., Galvan, A., Kohno, M., **Ray, L.A.**, & London, E.D. (2021). Diminished cortical response to risk and loss during risky decision making in alcohol use disorder. *Drug and Alcohol Dependence*, *218*, 108391.
201. **Ray, L.A.**, Du, H., Green, R., Roche, D.J.O., & Bujarski, S. (2021). Do behavioral pharmacology findings predict clinical trials outcomes? A proof-of-concept in medication development for alcohol use disorder. *Neuropsychopharmacology*, *46*(3), 519-527.
202. Baskerville, W., Nieto, S.J., Ho, Diana, Towns, B., Grodin, E.N., Li, C., Burnette, E., Donato, S., **Ray, L.A.** (2021). Baseline drinking patterns in non-treatment seeking heavy drinkers. *Alcohol & Alcoholism*, *56*(1), 57-63.
203. Nieto, S., Grodin, E. Green, R., & **Ray, L.A.** (2021). Evaluation of the Addiction Neuroclinical Assessment (ANA) framework through deep phenotyping of problem drinkers. *Drug and Alcohol Dependence*, *221*:108603.
204. **Ray, L.A.** & Grodin, E.N. Clinical neuroscience of addiction: What clinical psychologists need to know and why. (2021). *Annual Review of Clinical Psychology*, *17*, 465-493.
205. Grodin, E.N., Bujarski, S., Towns, B., Burnette, E., Nieto, S., Lim, A., Lin, J., Miotto, K., Gillis, A., Irwin, M.R., Evans, C., & **Ray, L.A.** (2021). A novel neuroimmune modulator reduces heavy drinking and alcohol cue-elicited neural activation. *Translational Psychiatry*, *11*(1):355.
206. Grodin, E.N., Burnette, E.M., Green R., Lim, A.C., Miotto, K., & **Ray, L.A.** (2021). Combined varenicline and naltrexone attenuates alcohol cue-elicited activation in heavy drinking smokers. *Drug and Alcohol Dependence*, *225*:108825.
207. Green, R., Du, H., Grodin, E., Nieto, S., Bujarski, S., Roche, D.J.O., & **Ray, L.A.** (2021). A meta-regression of methodological features predicting the effects of pharmacotherapies on subjective response to alcohol. *Alcoholism: Clinical & Experimental Research*, *5*(7), 1336-1347.
208. Meredith, L.R., Grodin, E.N., Karno, M.P., Montoya, A.K., MacKillop, J., Lim, A.C., & **Ray, L.A.** (2021). Preliminary study of alcohol problem severity and response to brief intervention. *Addiction Science & Clinical Practice*, *16*(1):54.
209. Metha, K., Hoadley, A., **Ray, L.A.**, Kiluk, B.D., Carroll, K.M., & Magill, M. (2021). Cognitive-behavioral interventions targeting alcohol or other drug use and co-occurring mental health disorders: A meta-analysis. *Alcohol & Alcoholism*, *56*(5):535-544.
210. Grodin, E.N., Burnette, E., Towns, B., Venegas, A., & **Ray, L.A.** (2021). Effect of alcohol, tobacco, and cannabis co-use on gray matter volume in heavy drinkers. *Psychology of Addictive Behaviors*, *35*(6):760-768.
211. **Ray, L.A.**, Green, R., Enders, C., Leventhal, A.M., Grodin, E., Li, G., Lim, A., Hartwell, E., Venegas, A., Meredith, L., Nieto, S., Shoptaw, S., Ho, D. & Miotto, K. (2021). Efficacy of combining varenicline and naltrexone for smoking cessation and drinking reduction: A randomized clinical trial. *American Journal of Psychiatry*, *178*(9): 818-828.
212. Nieto, S.J., Baskerville, W., Donato, S., **Ray, L.A.** (2021). Lifetime heavy drinking years predict alcohol use disorder severity over and above current alcohol use. *American Journal of Drug and Alcohol Abuse*, *47*(5): 630-637.
213. Donato, S., Green, R., & **Ray, L.A.** (2021). Alcohol use disorder severity moderates clinical response to varenicline. *Alcoholism: Clinical & Experimental Research*, *45*(9), 1877-1887.
214. Meredith, L.R., Burnette, E., Grodin, E.N., Irwin, M.R., & **Ray, L.A.** (2021). Immune treatments for alcohol use disorder: A translational framework. *Brain, Behavior, and Immunity*, *97*: 349-364.
215. Meredith, L.R., Baskerville, W.A., Friedman, T.C., Hurley, B., Dixon, T., Mtume, N., Rodriguez, L., Lopez, B., Hsieh, S., & **Ray, L.A.** (2021). Safety net provider attitudes toward smoking cessation treatment. *Frontiers in Psychiatry*, *12*:744816.

216. Burnette, E.M., **Ray, L.A.**, Irwin, M.R., & Grodin, E.N. (2021). Ibudilast attenuates alcohol cue-elicited frontostriatal functional connectivity in alcohol use disorder. Alcoholism: Clinical & Experimental Research, 45(10): 2017-2028.
217. Venegas, A., Meredith, L.R., Green, R., Cooper, Z.D, & **Ray, L.A.** (2021). Sex-dependent effects of alcohol administration on the urge to use cannabis. Experimental and Clinical Psychopharmacology, 29(6): 689-695.
218. Nieto, S.J., Aguirre, C., Grodin, E.N., Izquierdo, A., & **Ray, L.A.** (2021). Translational opportunities in animal and human models to study alcohol use disorder. Translational Psychiatry, 11(1): 496.
219. Venegas, A., Donato, S., Meredith, L., & **Ray, L.A.** (2021). Understanding low treatment seeking rates for alcohol use disorder: A narrative review of the literature and opportunities for improvement. American Journal of Drug and Alcohol Abuse, 47(6): 664-679.
220. Nieto, S.J., Venegas, A., Burnette, E.M., MacKillop, J., & **Ray, L.A.** (2022). Additive roles of tobacco and cannabis co-use in relation to delay discounting in a sample of heavy drinkers. Psychopharmacology, 239(5):1387-1395.
221. Leventhal, A.M., Conti, D.V., **Ray, L.A.**, Baurley, J.W., Bello, M.S., Cho, J., Zhang, Y. Pester, M., & Lebovitz, L., Budiarto, A., Mahesworo, B., & Pardamean, B. (2022). Genetic Associations with Tobacco Withdrawal in Non-Hispanic African American Smokers: A Behavioral Pharmacology Study. Experimental & Clinical Psychopharmacology, 30(5): 673-681.
222. Burnette, E.M., Nieto, S.J., Grodin, E.N., Meredith, L.R., Hurley, B., Miotto, K., Gillis, A.J., & **Ray, L.A.** (2022). Novel agents for the pharmacological treatment of alcohol use disorder. Drugs, 82(3): 251-274.
223. Nieto, S.J., Grodin, E.N., Ho, D., Baskerville, W., & **Ray, L.A.** (2022). Moderators of subjective response to alcohol in the human laboratory. Alcoholism: Clinical & Experimental Research, 46(3): 468-476.
224. Nieto, S.J., & **Ray, L.A.** (2022). Applying the addiction neuroclinical assessment to derive neurofunctional domains in individuals who use methamphetamine. Behavioral Brain Research, 427: 113876.
225. Meredith, L., Grodin, E., Montoya, A., Miranda, R., Squeglia, L., Towns, B., Evans, C., & **Ray, L.A.** (2022). The effect of neuroimmune modulation on subjective response to alcohol in the natural environment. Alcoholism: Clinical & Experimental Research, 46(5): 876-890.
226. Meredith, L.R., Green, R., Grodin, E.N., Chorpita, M., Miotto, K., & **Ray, L.A.** (2022). Ibudilast moderates the effect of mood on alcohol craving during stress exposure. Experimental & Clinical Psychopharmacology, 30(5):620-631.
227. Leventhal, A., Cho, J., **Ray, L.A.**, Pacula, R., Lee, B., Terrault, N., Pedersen, E., Lee, J.O., Davis, J., Jin, H., Huh, J., Wilson, J., Whaley, R. (2022). Alcohol use trajectories among U.S. adults during the first 42 weeks of the COVID-19 pandemic. Alcoholism: Clinical & Experimental Research, 46(6): 1062-1072.
228. Grodin, E., Nieto, S.J., Meredith, L.R., Burnette, E., O'Neill, J., Alger, J., London, E.D., Miotto, K., Evans, C.J., Irwin, M.R., & **Ray, L.A.** (2022). Effects of Ibudilast on central and peripheral markers of inflammation in alcohol use disorder: Randomized Clinical Trial. Addiction Biology, 27(4): e13182.
229. Nieto, S.J., Venegas, A., Hudson, J., & **Ray, L.A.** (2022). Cannabis use and subjective response to alcohol in the human laboratory. Drug and Alcohol Dependence, 236:109481.
230. Green, R. Montoya, A., & **Ray, L.A.** (2022). The relationship between drinking and smoking in a clinical trial for smoking cessation and drinking reduction. Experimental & Clinical Psychopharmacology, 30(6): 873-883.
231. Green, R., Roche, D.J.O., & **Ray, L.A.** (2022). The effects of menstrual cycle hormones on responses to varenicline and naltrexone among female heavy drinking smokers. Alcohol & Alcoholism, 57(5): 609-614.
232. Nieto, S.J., Grodin, E.N., Burnette, E.M., Cahill, C.M., & **Ray, L.A.** (2022). Pain catastrophizing is associated with increased alcohol cue-elicited neural activity among individuals with alcohol use disorder. Alcohol & Alcoholism, 57(6): 727-733.

233. Baskerville, W.A., Grodin, E., & **Ray, L.A.** (2022). Global sleep quality is associated with tonic craving, but not cue-induced craving. Addictive Behaviors, *133*: 107372.
234. Donato, S., Nieto, S., & **Ray, L.A.** (2022). The brief alcohol use disorder severity scale: An initial validation evaluation. Alcohol & Alcoholism, *57*(6): 762-767.
235. Venegas, A., Du, H., Cooper, Z., & **Ray, L.A.** (2022). Cannabis and alcohol co-use: The effects of intensity of cannabis use among heavy drinkers. Addictive Behaviors, *135*: 107443.
236. Green, R., Lin, J., Montoya, A., Bello, M., Grodin, E., Ryu, H., Ho, D., Leventhal, A., **Ray, L.A.** (2022). Characteristics associated with treatment seeking for smoking cessation among heavy drinking research participants. Frontiers in Psychiatry, *13*: 951364.
237. Grodin, E., Donato, S., Du, H., Green, R., Bujarski, S., & **Ray, L.A.** (2022). A meta-regression of trial features predicting the effects of alcohol use disorder pharmacotherapies on drinking outcomes in randomized clinical trials: A secondary data analysis. Alcohol & Alcoholism, *57*(5): 589-594.
238. Nieto, S.J., Enders, C., Witkiewitz, K., O'Malley, S., & **Ray, L.A.** (2022). Combination treatment with varenicline and naltrexone reduces World Health Organization risk drinking levels. Alcoholism: Clinical and Experimental Research, *46*(12): 2258-2266.
239. MacKillop, J., Agabio, R., Feldstein-Ewing, S.W., Heilig, M., Kelly, J.F., Leggio, L., Lingford-Hughes, A., Palmer, A.A., Parry, C.D., **Ray, L.A.**, & Rehm, J. (2022). Hazardous drinking and alcohol use disorders. Nature Review Disease Primers, *8*(1): 80.
240. Venegas, A. & **Ray, L.A.** (2023). Cross-substance primed and cue-induced craving among alcohol and cannabis co-users: An experimental psychopharmacology approach. Experimental & Clinical Psychopharmacology, *31*(3): 683-693.
241. Levitt, E. E., Oshri, A., Amlung, M., **Ray, L.A.**, Sanchez-Roige, S., Palmer, A.A., & MacKillop, J. (2023). Evaluation of delay discounting as a transdiagnostic research domain criteria indicator in 1388 general community adults. Psychological Medicine, *53*(4): 1649-1657.
242. Grodin, E., Meredith, L., Burnette, E., Miotto, K., Irwin, M., & **Ray, L.A.** (2023). Baseline C-reactive protein levels are predictive of treatment response to a neuroimmune modulator in individuals with an alcohol use disorder: A preliminary study. American Journal of Drug and Alcohol Abuse, *49*(3): 333-344.
243. Grodin, E., Burnette, E., O'Neill, J., Alger, J., & **Ray, L.A.** (2023). Alcohol craving and severity are associated with dorsal anterior cingulate choline levels in individuals with alcohol use disorder. Alcohol & Alcoholism, *58*(3): 289-297.
244. Baskerville, W.A., Grodin, E., Lin, J., Miotto, K., Mooney, L.J., **Ray, L.A.** (2023). Alcohol use among treatment-seeking individuals with opioid use disorder. Journal of Studies on Alcohol & Drugs, *84*(4): 579-584.
245. **Ray, L.A.**, Nieto, S.J., Meredith, L.R., Burnette, E., Donato, S., Magill, M., & Du, H. (2023). Are medication effects on subjective response to alcohol and cue-induced craving associated? A meta regression study. Psychopharmacology, *240*(9): 1921-1930
246. Meredith, L.R., Burnette, E.M., Nieto, S.J., Donato, S., Du, H., Grodin, E.N., Green, R., Magill, M., & **Ray, L.A.** (in press). Testing pharmacotherapies for alcohol use disorder with cue exposure paradigms: A systematic review and quantitative synthesis of human laboratory trial methodology. Alcohol: Clinical & Experimental Research.
247. Meredith, L.R., Hurley, B., Friedman, T.C., Lee, M.L., Rodriguez, L., Lopez, B., Mtume, N., Dixon, T., Belani, H.K., Hsieh, S., & **Ray, L.A.** (in press). Implementation of specialty tobacco use disorder services (STUDS) in a community health setting: Support for enhanced prescription practices. Journal of Addiction Medicine.
248. Burnette, E., Grodin, E., Olmstead, R., **Ray, L.A.**, Irwin, M. (in press). Alcohol use disorder is associated with enhanced sensitivity to cellular lipopolysaccharide challenge. Alcohol: Clinical & Experimental Research.
249. Grodin, E.N., Montoya, A.K., Cruz, A.M., Donato, S. Baskerville, W., & **Ray, L.A.** (in press). Identifying treatment responders to varenicline for alcohol use disorder using two machine learning approaches. Clinical Psychological Science.

Peer-Reviewed Commentaries & Editorials

1. Hutchison, K.E. & **Ray, L.A.** (2011). New approaches to identifying rare genetic variants associated with nicotine dependence. *Biological Psychiatry*, 70(6), 500-1.
2. **Ray, L.A.** (2015). A matter of outlook. *Alcoholism: Clinical and Experimental Research*, 39(4), 590.
3. **Ray, L.A.** & Bujarski, S.E. (2015). Mechanisms of topiramate effects: Refining medications development for alcoholism. *Addiction Biology*.
4. **Ray, L.A.**, Lim, A.C., & Shoptaw, S. (2019). What defines a clinically meaningful outcome in the treatment of substance use disorders: 'Getting your life back.' *Addiction*, 114(1), 18-20.
5. **Ray, L.A.**, Green, R., & Grodin, E. (2021). Neurobiological models of alcohol use disorder in humans. *American Journal of Psychiatry*, 178(6), 483-484.
6. Burnette, E.M., Grodin, E.N., Eisenberger, N., & **Ray, L.A.** (2021). Endotoxin for alcohol research: A call for experimental medicine using lipopolysaccharide challenge. *Alcohol & Alcoholism*, 56(6): 715-717.
7. Leko, A.H., **Ray, L.A.**, Leggio, L. The vicious cycle between (neuro)inflammation and alcohol use disorder: An opportunity toward the development of new medications? (2023). *Alcohol: Clinical and Experimental Research*, 47(5): 843-847.
8. Grodin, E., Donato, S., Du., H. Green, R., Bujarski, S., & **Ray, L.A.** Response to Letter to the Editors regarding "A Meta-Regression of Trial Features Predicting the Effects of Alcohol Use Disorder Pharmacotherapies on Drinking Outcomes in Randomized Clinical Trials: A Secondary Data Analysis." (in press). *Alcohol & Alcoholism*.

Books Edited

1. MacKillop, J., Kenna, G.A., Leggio, L., & **Ray, L.A.** (Eds.). (2017). Integrating Psychological and Pharmacological Treatments for Addictive Disorders: An Evidence-Based Guide. Routledge.

Book Chapters

1. **Ray, L.A.**, Hutchison, K.E., & Hauser, M. (2008). Alcohol use disorders: history, theory, and diagnosis. In W.E. Craighead, D.J. Miklowitz, & L.C. Craighead (Eds.). *Psychopathology: History, Diagnosis, and Empirical Foundations* (pp. 495-523). John Wiley and Sons.
2. **Ray, L.A.** & Hutchison, K.E. (2009). Genetics of addiction. In L.M. Cohen, F.L. Collins, A. Young, D.E. McCheargue, T.R. Leffingwell, & K.L. Cook (Eds.). *The Pharmacology and Treatment of Substance Abuse: Evidence and Outcomes Based Perspectives* (pp. 109-126). Routledge.
3. MacKillop, J., McGeary, J.E., **Ray, L.A.** (2010). Genetic influences on addiction: Alcoholism as an exemplar. In D. Ross, P. Collins, & D. Spurrett (Eds.). *What is Addiction?* (pp. 53-98). MIT Press.
4. **Ray, L.A.** & Hutchison, K.E. (2010). Molecular genetics and the treatment of addiction. In B. Johnson (Ed.). *Addiction Medicine: Science and Practice, First Edition* (pp. 1101-1114). Springer.
5. MacKillop, J., Amlung, M.T., Murphy, C.M., Acker, J. & **Ray, L.A.** (2011). A Behavioral Economic Approach to Health Behavior. In: R. DiClemente, L.F. Salazar, and R.A. Crosby (Eds.) *Health Behavior Theory for Public Health: Principles, Foundations, and Applications* (pp. 131-161). Jones and Bartlett Publishers, LLC.
6. Monti, P.M. & **Ray, L.A.** (2012). The study of craving and its role in addiction. In K. D. Brownell & M.S. Gold (Eds.). *Food and Addiction* (pp. 53-58). Oxford University Press.
7. **Ray, L. A.**, & Courtney, K. E. (2013). Addiction. In Hal Pashler (Ed.), *Encyclopedia of the Mind, (Vol. 1, pp. 8-11)*. Sage.
8. Miotto, K.M., Heydari, A., Tartter, M., Chang, E., Thomas, P.S., & **Ray, L.A.** (2013). Adolescent Alcohol Use, In R. Rosner (Ed.). *Clinical Handbook of Adolescent Addiction* (pp.179-189). Wiley-Blackwell.
9. **Ray, L.A.**, Courtney, K., Bacio, G., & MacKillop, J. (2013). Assessment of Craving in Addiction Research. In J. MacKillop and H. de Witt (Eds.). *The Wiley-Blackwell Handbook of Addiction Psychopharmacology* (pp. 345-380). Wiley-Blackwell.

10. **Ray, L.A.**, Courtney, K.E., & Bacio, G. (2013). Alcohol use disorders. In W.E. Craighead, D.J. Miklowitz, & L.C. Craighead (Eds.). *Psychopathology: History, Diagnosis, and Empirical Foundations, 2nd Edition* (pp. 550-582). John Wiley and Sons.
11. **Ray, L.A.** & Heilig, M. (2014). Subjective responses to alcohol: Implications to alcoholism etiology and treatment development, In J. MacKillop and M. Munafo (Eds.). *Genetic Influences on Addiction: An Intermediate Phenotype Approach* (pp. 97-120). Wiley-Blackwell.
12. **Ray, L.A.**, Courtney, K.E., Roche, D., & Miotto, K. (2015). Application of functional neuroimaging to the treatment of addiction: Focus on pharmacotherapies. In S.W. Feldstein-Ewing, K. Witkiewitz, & F.M. Filbey (Eds.), *Neuroimaging and Psychosocial Addiction Treatment: An Integrative Guide for Researchers and Clinicians*. Palgrave.
13. MacKillop, J. & **Ray, L.A.** (2017). The etiology of addiction: A contemporary biopsychosocial approach. In J. MacKillop, G.A. Kenna, L. Leggio, & **L.A. Ray** (Eds.), *Integrating Psychological and Pharmacological Treatments for Addictive Disorders: An Evidence-Based Guide*. Routledge.
14. Yardley, M.M., Shoptaw, S.J., Heinzerling, K.G., & **Ray, L.A.** (2017). Addiction treatment in primary care. In J. MacKillop, G.A. Kenna, L. Leggio, & **L.A. Ray** (Eds.), *Integrating Psychological and Pharmacological Treatments for Addictive Disorders: An Evidence-Based Guide*. Routledge.
15. **Ray, L.A.**, Hartwell, E., Green, R.J., Venegas, A. (2019). State-of-the-art treatment of alcohol use disorder. In I. Danovitch & L.J. Mooney (Eds.), *The Assessment and Treatment of Addiction: Best Practices and New Frontiers* (pp. 123-135). Elsevier.
16. Miranda Jr., R., **Ray, L.A.**, O'Malley, S.S. (2019). The role of clinical human laboratory research in psychopharmacology. In S.M. Edwards & K.M. Carpenter (Eds.), *APA Handbook of Psychopharmacology* (pp. 87-107). American Psychological Association.
17. Burnette, E.M., Nieto, S.J., Grodin, E.N., Jentsch, D.J., & **Ray, L.A.** (2023). Intravenous alcohol self-administration using a progressive ratio schedule of reinforcement in clinical studies. In M.A. Cyders (Ed), *Translational Research Methods for Alcohol Use Disorders* (pp. 189-200). Neuromethods 201; Springer Protocols. Humana Press.
18. Nieto, S.J., Donato, S., Gillis, A.J., & **Ray, L.A.** (in press). Laboratory-based approaches to medications development for alcohol addiction. In S.M. Mueller & M. Heilig (Eds.), *Alcohol and Alcohol-related Diseases*. Springer.
19. Grodin, E.N., Meredith, L.R., Burnette, E.M., & **Ray, L.A.** (in press). Brain-immune mechanisms in alcohol use disorder, targeting neuroimmune signaling in alcohol use disorder: Opportunities for translation. In S.M. Mueller & M. Heilig (Eds.), *Alcohol and Alcohol-related Diseases*. Springer.

Manuscripts under Review or In Revision

1. **Ray, L.A.**, Grodin, E., Baskerville, W., Donato, S., Cruz, Al., & Montoya, A. Gabapentin for the treatment of alcohol use disorder: A machine learning approach.
2. **Ray, L.A.**, Baskerville, W.A., Nieto, S.J., Grodin, E., Enders, C., Kady, A., Meredith, L. Gillis, A., Leventhal, A., Ho, D., Miotto, K. A practice quit model to test early efficacy of medications for alcohol use disorder in a randomized clinical trial.
3. Grodin, E.N., Burnette, E.M., Rodriguez, C., Fuscher, J.A., & **Ray, L.A.** The gut microbiome in alcohol use disorder and alcohol-associated liver disease: A systematic review.
4. Nieto, S.J., Burnette, E.M., Grodin, E.N., & **Ray, L.A.** Neural correlates of the Addiction Neuroclinical Assessment (ANA) incentive salience factor among individuals with alcohol use disorder.
5. McManus, K., Venegas, A. Henry, B., Cooper, Z.D., Grodin, E.N., & **Ray, L.A.** The role of sex in daily levels of alcohol and cannabis co-use.
6. Grodin, E.N., McManus, K., & **Ray, L.A.** Cannabis use interacts with alcohol consumption to increase peripheral inflammation in individuals with alcohol use disorder.
7. Kirsch, D.E., Belnap, M., Burnette, E.M., Grodin, E.N., & **Ray, L.A.** Pharmacological treatments for alcohol use disorder: Considering the role of sex and gender.
8. Kirsch, D.E., **Ray, L.A.**, Wassum, K.M., & Grodin, E.N. Anterior cingulate cortex alcohol cue reactivity varies as a function of drink preference in alcohol use disorder.

TEACHING EXPERIENCE

Graduate Courses

Psychology 270C: Clinical Psychology Foundations, Addiction Module
 Psychology 298: Evidence-based Psychological Treatments for Adult Psychopathology
 Psychology 298: Grant Writing in Psychological Science
 Psychology 298: Biological Factors in Behavior
 Psychology 403: Detection and Treatment of Alcohol and Chemical Substance Dependency
 Psychology 401: Clinical Supervision, Psychotherapy Practicum
 Psychology 401: Clinical Supervision, Assessment Practicum

Undergraduate Courses

Psychology 162: Psychology of Addiction (Hybrid course: Online/in-person format)
 Psychology 127B: Abnormal Psychology, Biological Bases
 Psychology 162: Psychology of Addiction
 Psychology 189: Honors section for Psychology of Addiction
 Psychology 10: Introduction to Psychology

CLINICAL EXPERIENCE

July 2021-present **Attending Psychologist**, Addiction Psychiatry Clinic, UCLA Psychiatry Department
July 2008-present **Supervising Psychologist & Clinical Faculty**, UCLA Psychology Clinic
July 2008-present **Private Practice Psychologist**
July 2009-June 2016 **Co-Director and Clinical Supervisor**, Behavioral Medicine and Addiction Clinic at the UCLA Family Health Center, UCLA Department of Family Medicine
July 2007-June 2008 **Postdoctoral Fellow**
 Center for Alcohol and Addiction Studies, Brown University Medical School, Providence, Rhode Island
July 2007-June 2008 **Volunteer Psychologist**
 Rhode Island Free Clinic, Providence, Rhode Island
 Responsible for providing mental health services to multicultural and economically underserved population; clinical services also provided in Spanish and Portuguese.
July 2007-June 2008 **Supervised Private Practice**
 Butler Hospital Campus, Providence, Rhode Island
Jul 2006-Jun 2007 **Clinical Psychology Intern, Adult Track**
 Brown University Medical School, Department of Psychiatry and Human Behavior, Providence, Rhode Island
Rotations: Butler Partial Hospital Program; VA Medical Center Alcohol and Drug Treatment Program; Rhode Island Hospital Sleep and Anxiety Disorders Clinic; Butler Outpatient Clinic.

PROFESSIONAL ACTIVITIES

Grant Reviewing

NIDA Intramural Program, Board of Scientific Counselors (BSC) (2020-present)
 NIAAA, AA-3, Clinical, Treatment, and Health Services Research Committee, standing member (2013-2019)
 NIAAA, AA-2, Epidemiology, Prevention, and Behavior Research, ad hoc (2012)
 NIAAA, Work Group for Alcohol Research Centers, ZAA1 GG (60) (2012)
 NIAAA Special Emphasis Panel, ZAA1 DD(03) (2011)
 VA SPLC/Genetics CSSEC Review Panel (2011)
 Belgium Science Policy Office, ad hoc (2011)

Editing and Reviewing

Neuropsychopharmacology, Associate Editor
 Addiction, *Associate Editor* (2019-2023)
 Clinical Psychology Science and Practice, *Associate Editor*
 American Journal of Drug and Alcohol Abuse, *Associate Editor*
 Alcoholism: Clinical and Experimental Research, *Field Editor* (2015-2019)

Professional Affiliations

American College of Neuropsychopharmacology (ACNP, Full Member)
 American Psychological Association (APA, Fellow)
 Society of Addiction Psychology, APA (Div. 50, Fellow)
 Society of Clinical Psychology, APA (Div. 12)
 Research Society on Alcoholism (RSA)

Professional Committees

2023 Search Committee (Chair), Psychology Clinic Director, UCLA Psychology Dept
2021- President Elect, Research Society on Alcohol (RSA)
2021- Member, Board of Scientific Counselors (BSC), National Institute on Drug Abuse
2021- Board Member, Winter Conference on Brain Research
2019-2023 Faculty Review Committee, UCLA Graduate Summer Research Mentorship
2019 Conference Program Committee, Research Society on Alcoholism (RSA)
2018 Search Committee (Chair), Mood disorders search, UCLA Psychology Department
2018-2020 Merit Review Committee, UCLA Psychology Department
2018- Executive Committee (alternate), UCLA Psychology Department
2018- Undergraduate Studies Committee, UCLA Psychology Department
2016- Graduate Awards Committee, UCLA Psychology Department
2013- Monica Salinas Scholarship Fund Committee, UCLA Psychology Department
2008-2020 Graduate Studies Committee, UCLA Psychology Department
2008-2019 Diversity Committee, UCLA Psychology Department
2008- Admissions Committee, Clinical Psychology, UCLA Psychology Department
2016-2017 Placements Committee (Chair), UCLA Psychology Department, Clinical Area
2015-2017 Executive Committee (alternate), UCLA Psychology Department
2016-2017 Merit Review Committee (alternate), UCLA Psychology Department
2016 Chair, Program Committee, APA Division 50, Society for Addiction Psychology
2013-2014 Co-Chair, Clinic and Placements Committee, UCLA Psychology Department
2013-2017 Elected Board Member, Research Society on Alcoholism (RSA)
2013-2017 Scientific Advisory Committee, UCLA Clinical and Translational Science Institute
2012-2013 Search Committee, Staglin Chair, UCLA Psychology Department
2012 Conference Program Committee, Research Society on Alcoholism (RSA)
2011-2014 Education Committee, Research Society on Alcoholism (RSA)
2011 Search Committee, Eleanor Leslie Term Chair, UCLA Brain Research Institute
2010-2014 Awards Committee, UCLA Brain Research Institute
2009-2011 Search Committee, UCLA Learning and Behavior Area
2009-2014 Clinic Committee, UCLA Clinical Psychology Area
2006-2007 Internship Admissions Committee, Department of Psychiatry, Brown University

UCLA Thesis and Dissertation Committees

2023- Chair, dissertation committee, *Malia Belnap*, Neuroscience IDP
2022- Chair, dissertation committee, *Suzanna Donato*, Clinical Psychology
2021- Chair, dissertation committee, *Lindsay Meredith*, Clinical Psychology

2019-2023	Chair, dissertation committee, <i>Elizabeth Burnette</i> , Neuroscience IDP
2019-2021	Chair, dissertation committee, <i>ReJoyce Green</i> , Clinical Psychology
2019-2020	Chair, dissertation committee, <i>Aaron Lim</i> , Clinical Psychology
2018-2019	Chair, thesis committee, <i>Lindsay Meredith</i> , Clinical Psychology
2017-2018	Thesis committee, <i>Claudia Aguirre</i> , Behavioral Neuroscience
2017-2018	Chair, thesis committee, <i>Alexandra Venegas</i> , Clinical Psychology
2016-2017	Chair, thesis committee, <i>ReJoyce Green</i> , Clinical Psychology
2015-2016	Chair, thesis committee, <i>Aaron Lim</i> , Clinical Psychology
2017-2018	Dissertation committee, <i>Helene Chokron Garneau</i> , Public Health
2017-2018	Dissertation committee, <i>Jenna Cummings</i> , Health Psychology
2017-2019	Dissertation committee, <i>Evan Hart</i> , Behavioral Neuroscience
2016-2017	Chair, dissertation committee, <i>Emily Hartwell</i> , Clinical Psychology
2015-2017	Chair, dissertation committee, <i>Spencer Bujarski</i> , Clinical Psychology
2014-2016	Chair, dissertation committee, <i>Kelly Courtney</i> , Clinical Psychology
2014-2016	Chair, dissertation committee, <i>Nathasha Moallem</i> , Clinical Psychology
2014-2016	Chair, dissertation committee, <i>Vincent Allen</i> , Clinical Psychology
2013-2014	Chair, thesis committee, <i>Emily Hartwell</i> , Clinical Psychology
2012-2014	Chair, dissertation committee, <i>Guadalupe Bacio</i> , Clinical Psychology
2012-2014	Dissertation committee, <i>Betty Liao</i> , Clinical Psychology
2012-2013	Dissertation committee, <i>Rachel Higier</i> , Clinical Psychology
2012-2014	Dissertation committee, <i>Tristen Inagaki</i> , Social Psychology
2012-2013	Thesis committee, <i>Carolyn Davies</i> , Clinical Psychology
2011-2012	Chair, thesis committee, <i>Spencer Bujarski</i> , Clinical Psychology
2010-2011	Chair, thesis committee, <i>Kelly Courtney</i> , Clinical Psychology
2010-2011	Chair, thesis committee, <i>Nathasha Moallem</i> , Clinical Psychology
2009-2013	Co-Chair, dissertation committee, <i>James Ashenhurst</i> , BRI Neuroscience Program
2011-2013	Dissertation committee, <i>Angie Morales</i> , Interdepartmental Neuroscience Program
2011-2013	Dissertation committee, <i>Amy Jimenez</i> , Clinical Psychology
2011-2013	Dissertation committee, <i>Stephanie Groman</i> , Behavioral Neuroscience
2011-2012	Dissertation committee, <i>Chris Conway</i> , Clinical Psychology
2009-2010	Chair, thesis committee, <i>Molly Tartter</i> Clinical Psychology
2010-2011	Dissertation committee, <i>Evan Lutkenhoff</i> , Interdepartmental Neuroscience Program
2009-2010	Thesis committee, <i>Alex Zvinyatskovskiy</i> , Clinical Psychology
2008-2009	Thesis committee, <i>Kate Humphreys</i> , Clinical Psychology
2009-2011	Dissertation committee, <i>Rick Laughlin</i> , Behavioral Neuroscience
2009-2011	Dissertation committee, <i>Rachael Willhite-Viehman</i> , Clinical Psychology
2009-2011	Dissertation committee, <i>Caitlin Ferriter</i> , Clinical Psychology

Professional Activities Related to Diversity, Equity & Inclusion

2021-2022	Research Mentor , PROPS, UCLA Psychology Department
2021-2023	Research Mentor , Enhancing Diversity in Alcohol Research (EDAR; R25)
2021-2023	Research Mentor , Substance Abuse Research Training Program (SART; R25)
2020	Research Mentor , Substance Abuse Research Training Program (SART; R25)
Summer 2019	Research Mentor , HBCU-UCLA Neuroscience Pathways summer research
2018-19	Research Mentor , PROPS, UCLA Psychology Department
2017-18	Research Mentor , PROPS, UCLA Psychology Department
2016-17	Research Mentor , Undergraduate Research Fellowship Program, UCLA Undergraduate Research Centers
2016-17	Research Mentor , PROPS, UCLA Psychology Department
2014-15	Research Mentor , PROPS, UCLA Psychology Department

- 2013** **Research Mentor**, UCLA Brain Research Institute Summer Undergraduate Research Experience (BRI-SURE)
- 2013** **Research Mentor**, NIDA Summer Research Program
- 2012** **Research Mentor**, NIDA Summer Research Program
- 2011** **Research Mentor**, NIDA Summer Research Program
- 2010** **Research Mentor**, UCLA Summer Programs for Research (SPUR/GR)
- 2009** **Research Mentor**, Alliance for Graduate Education and the Professoriate (AGEP)
- 2003 – 2004** **Doctoral Mentor**, McNair Research Program, University of Colorado, Boulder
- 2003** **Doctoral Mentor**, Multicultural Access to Research Training, CU Boulder
- 2003** **Society for the Advancement of Chicanos and Native Americans in Science**
- 2003** **The Leadership Alliance Symposium**, Chantilly, Virginia.

Languages Spoken

Portuguese
Spanish